<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Control Trials Cardiovasc Med</journal-id><journal-title>Current Controlled Trials in Cardiovascular Medicine</journal-title><issn pub-type="ppub">1468-6708</issn><issn pub-type="epub">1468-6694</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">11806817</article-id><article-id pub-id-type="pmc">64833</article-id><article-id pub-id-type="publisher-id">cvm-2-6-298</article-id><article-id pub-id-type="doi">10.1186/cvm-2-6-298</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>How well can blood pressure be controlled? Progress report on the Systolic Hypertension in Europe Follow-Up Study (Syst-Eur 2)</article-title></title-group><contrib-group><contrib id="A1" corresp="yes" contrib-type="author"><name><surname>Thijs</surname><given-names>Lutgarde</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>Thijs@med.kuleuven.ac.be</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Staessen</surname><given-names>Jan A</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A3" contrib-type="author"><name><surname>Beleva</surname><given-names>Sonia</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib id="A4" contrib-type="author"><name><surname>Birkenhäger</surname><given-names>Willem H</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib id="A5" contrib-type="author"><name><surname>Bulpitt</surname><given-names>Christopher J</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib id="A6" contrib-type="author"><name><surname>Celis</surname><given-names>Hilde</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A7" contrib-type="author"><name><surname>Fletcher</surname><given-names>Astrid E</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib id="A8" contrib-type="author"><name><surname>Kermova</surname><given-names>Rumjana</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib id="A9" contrib-type="author"><name><surname>Leonetti</surname><given-names>Gastone</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib id="A10" contrib-type="author"><name><surname>Laks</surname><given-names>Tovio</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib id="A11" contrib-type="author"><name><surname>Mantov</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib id="A12" contrib-type="author"><name><surname>Nachev</surname><given-names>Choudomir</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib id="A13" contrib-type="author"><name><surname>Sarti</surname><given-names>Cinzia</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib id="A14" contrib-type="author"><name><surname>Tuomilehto</surname><given-names>Jaakko</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib id="A15" contrib-type="author"><name><surname>Fagard</surname><given-names>Robert H</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib id="A16" contrib-type="author"><collab>on behalf of the Systolic Hypertension in Europe Investigators</collab><xref ref-type="aff" rid="I12">12</xref></contrib></contrib-group><aff id="I1"><label>1</label>Hypertensie en Cardiovasculaire Revalidatie Eenheid, Katholieke Universiteit Leuven, Leuven, Belgium</aff><aff id="I2"><label>2</label>District Hospital, Virdin, Bulgaria</aff><aff id="I3"><label>3</label>Erasmus University, Rotterdam, the Netherlands</aff><aff id="I4"><label>4</label>Geriatric Unit, Hammersmith Hospital, London, UK</aff><aff id="I5"><label>5</label>Department of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK</aff><aff id="I6"><label>6</label>Clinic of Rheumatology and Cardiology, Medical University, Pleven, Bulgaria</aff><aff id="I7"><label>7</label>Istituto Auxologico Italiano and the Centro di Fisiologia Clinica e Ipertensione, Ospedale Maggiore, Universitá di Milano, Italy</aff><aff id="I8"><label>8</label>Hypertension Unit, Department of Internal Medicine, Tallinn Central Hospital, Tallinn, Estonia</aff><aff id="I9"><label>9</label>Division of Cardiology, Department of Internal Medicine, Higher Medical Institute, Stara Zagora, Bulgaria</aff><aff id="I10"><label>10</label>Department of Internal Medicine, Alexandrov's University Hospital, Sofia, Bulgaria</aff><aff id="I11"><label>11</label>Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland</aff><aff id="I12"><label>12</label>See Appendix</aff><pub-date pub-type="ppub"><year>2001</year></pub-date><pub-date pub-type="epub"><day>18</day><month>10</month><year>2001</year></pub-date><volume>2</volume><issue>6</issue><fpage>298</fpage><lpage>306</lpage><ext-link ext-link-type="uri" xlink:href="http://www.trialsjournal.com/content/2/6/298"></ext-link><history><date date-type="received"><day>4</day><month>5</month><year>2001</year></date><date date-type="rev-request"><day>13</day><month>8</month><year>2001</year></date><date date-type="rev-recd"><day>25</day><month>9</month><year>2001</year></date><date date-type="accepted"><day>28</day><month>9</month><year>2001</year></date></history><permissions><copyright-statement>Copyright © 2001 Thijs et al, licensee BioMed Central Ltd</copyright-statement><copyright-year>2001</copyright-year><copyright-holder>Thijs et al, licensee BioMed Central Ltd</copyright-holder></permissions><abstract><sec><title><offsets xml_i="5908" xml_f="5918" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5929" xml_f="6535" txt_i="22" txt_f="628">The randomised, double-blind, placebo-controlled Systolic Hypertension in Europe trial (Syst-Eur 1) proved that blood pressure (BP) lowering therapy starting with nitrendipine reduces the risk of cardiovascular complications in elderly patients with isolated systolic hypertension. In an attempt to confirm the safety of long-term antihypertensive therapy based on a dihydropyridine, the Syst-Eur patients remained in open follow-up after the end of Syst-Eur 1. This paper presents the second progress report of this follow-up study (Syst-Eur 2). It describes BP control and adherence to study medications.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="6576" xml_f="6583" txt_i="630" txt_f="637">Methods</offsets></title><p><offsets xml_i="6594" xml_f="6974" txt_i="638" txt_f="1015">After the end of Syst-Eur 1 all patients, treated either actively or with placebo, were invited either to continue or to start antihypertensive treatment with the same drugs as previously used in the active treatment arm. In order to reach the target BP (sitting SBP &lt;150 mmHg), the first line agent, nitrendipine, could be associated with enalapril and/or hydrochlorothiazide.</offsets></p></sec><sec><title><offsets xml_i="6996" xml_f="7003" txt_i="1017" txt_f="1024">Results</offsets></title><p><offsets xml_i="7014" xml_f="7494" txt_i="1025" txt_f="1505">Of the 3787 eligible patients, 3516 (93%) entered Syst-Eur 2. At the last available visit, 72% of the patients were taking nitrendipine. SBP/DBP at entry in Syst-Eur 2 averaged 160/83 mmHg in the former placebo group and 151/80 mmHg in the former active-treatment group. At the last follow-up visit SBP/DBP in the patients previously randomised to placebo or active treatment had decreased by 16/5 mmHg and 7/5 mmHg, respectively. The target BP was reached by 74% of the patients.</offsets></p></sec><sec><title><offsets xml_i="7516" xml_f="7526" txt_i="1507" txt_f="1517">Conclusion</offsets></title><p><offsets xml_i="7537" xml_f="7811" txt_i="1518" txt_f="1792">Substantial reductions in systolic BP may be achieved in older patients with isolated systolic hypertension with a treatment strategy starting with the dihydropyridine calcium-channel blocker, nitrendipine, with the possible addition of enalapril and/or hydrochlorothiazide.</offsets></p></sec></abstract><kwd-group><kwd>calcium-channel blockers</kwd><kwd>elderly</kwd><kwd>isolated systolic hypertension</kwd></kwd-group></article-meta></front><body><sec><title><offsets xml_i="7990" xml_f="8002" txt_i="1801" txt_f="1813">Introduction</offsets></title><p><offsets xml_i="8013" xml_f="8269" txt_i="1814" txt_f="2070">The double-blind, placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial proved that antihypertensive treatment starting with nitrendipine reduced the risk of cardiovascular complications in older patients with isolated systolic hypertension [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="8300" xml_f="8301" txt_i="2070" txt_f="2071">1</offsets></xref><offsets xml_i="8308" xml_f="8309" txt_i="2071" txt_f="2072">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="8340" xml_f="8341" txt_i="2072" txt_f="2073">2</offsets></xref><offsets xml_i="8348" xml_f="8425" txt_i="2073" txt_f="2150">]. Similar findings were obtained in two placebo-controlled trials in China [</offsets><xref ref-type="bibr" rid="B3"><offsets xml_i="8456" xml_f="8457" txt_i="2150" txt_f="2151">3</offsets></xref><offsets xml_i="8464" xml_f="8465" txt_i="2151" txt_f="2152">,</offsets><xref ref-type="bibr" rid="B4"><offsets xml_i="8496" xml_f="8497" txt_i="2152" txt_f="2153">4</offsets></xref><offsets xml_i="8504" xml_f="9309" txt_i="2153" txt_f="2958">], in which antihypertensive treatment was also initiated with a dihydropyridine calcium-channel blocker. For a variety of ethical and documentary reasons, it was decided to extend the Syst-Eur trial into an open-label, active treatment, follow-up study in the same population and based upon the original active trial medication. The vast majority of patients volunteered to participate in this open follow-up study, Systolic Hypertension in Europe Phase 2 (Syst-Eur 2), which will last until the end of 2001. In this article, which is the second progress report of Syst-Eur 2, we aim to describe blood pressure (BP) control and adherence to study medications during the first three years of follow-up and, also, to explore whether BP control was influenced by diabetic status, or smoking/drinking habits.</offsets></p></sec><sec sec-type="methods"><title><offsets xml_i="9350" xml_f="9357" txt_i="2960" txt_f="2967">Methods</offsets></title><sec><title><offsets xml_i="9377" xml_f="9407" txt_i="2968" txt_f="2998">Design of the Syst-Eur 2 study</offsets></title><p><offsets xml_i="9418" xml_f="9451" txt_i="2999" txt_f="3032">The protocols of the Syst-Eur 1 [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="9482" xml_f="9483" txt_i="3032" txt_f="3033">1</offsets></xref><offsets xml_i="9490" xml_f="9508" txt_i="3033" txt_f="3051">] and Syst-Eur 2 [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="9539" xml_f="9540" txt_i="3051" txt_f="3052">5</offsets></xref><offsets xml_i="9547" xml_f="9740" txt_i="3052" txt_f="3245">] studies were approved by the Ethics Committees of the University of Leuven and by the participating centres, and implemented according to the principles outlined in the Helsinki declaration [</offsets><xref ref-type="bibr" rid="B6"><offsets xml_i="9771" xml_f="9772" txt_i="3245" txt_f="3246">6</offsets></xref><offsets xml_i="9779" xml_f="10345" txt_i="3246" txt_f="3812">]. Patients were eligible for the Syst-Eur 1 trial if they were at least 60 years of age and had a sitting systolic BP within the range 160–219 mmHg and a diastolic BP below 95 mmHg (with a systolic pressure of 140 mmHg or higher while they were standing). Patients were recruited from 198 centres in 23 countries across Western and Eastern Europe. Eligible patients were stratified by centre, sex and previous cardiovascular complications, and were randomised to double-blind treatment with either active medication or placebo. After the termination of Syst-Eur 1 [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="10376" xml_f="10377" txt_i="3812" txt_f="3813">1</offsets></xref><offsets xml_i="10384" xml_f="11588" txt_i="3813" txt_f="5017">] in Spring 1997, all the patients who were still in follow-up were requested to continue or to start antihypertensive therapy with the same drugs as previously used in the active-treatment arm. The goal of antihypertensive treatment during Syst-Eur 2 is to lower the sitting systolic BP (average of two readings, obtained after rest for five minutes) to less than 150 mmHg. The target pressure should be achieved by the stepwise titration of nitrendipine (10–40 mg/day), the first-line study medication, with the possible addition of either enalapril (5–20 mg/day) or hydrochlorothiazide (12.5–25 mg/day), or both of these drugs. If side effects occur during monotherapy with nitrendipine, the daily dose should first be back-titrated. If side effects persist at this lower dose, nitrendipine may be discontinued and enalapril started. Similarly, the second-line medication may be withdrawn because of side effects, and hydrochlorothiazide started. The open-label study medication may be associated with, or replaced by, any other antihypertensive or cardiovascular drug if a treatment-resistant patient requires it to reach the goal BP, or if a patient requires treatment for a cardiovascular disorder.</offsets></p><p><offsets xml_i="11595" xml_f="12066" txt_i="5018" txt_f="5489">During the first year of Syst-Eur 2, clinic visits were scheduled every three months; from the second year onwards, reports are due every six months (i.e. supervised follow-up). Patients who withdraw from the study and who no longer participate in clinic visits, proceed to the non-supervised follow-up, during which the investigator has to collect, at annual intervals, information on vital status, occurrence of major events and the use of antihypertensive medications.</offsets></p></sec><sec><title><offsets xml_i="12088" xml_f="12101" txt_i="5491" txt_f="5504">Data analysis</offsets></title><p><offsets xml_i="12112" xml_f="12608" txt_i="5505" txt_f="6001">Database management and statistical analysis were performed using SAS software version 8.01 (Cary, NC, USA). The last available BP measurements before the end of Syst-Eur1 were taken as the baseline pressures in Syst-Eur2. Baseline blood and urine tests were those obtained nearest to 14 February 1997, the date on which Syst-Eur1 ended. The BP changes during follow-up were analysed using the difference between baseline and the last available measurements. Means were compared by the Student's </offsets><italic><offsets xml_i="12616" xml_f="12617" txt_i="6001" txt_f="6002">t</offsets></italic><offsets xml_i="12626" xml_f="12744" txt_i="6002" txt_f="6120">-test. Between-group proportions were compared by the chi-square test, and within-group proportions by McNemar's test.</offsets></p></sec></sec><sec><title><offsets xml_i="12772" xml_f="12779" txt_i="6123" txt_f="6130">Results</offsets></title><sec><title><offsets xml_i="12799" xml_f="12812" txt_i="6131" txt_f="6144">Study profile</offsets></title><p><offsets xml_i="12823" xml_f="12896" txt_i="6145" txt_f="6218">A total of 4695 patients had been randomised in the Syst-Eur trial (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="12926" xml_f="12927" txt_i="6218" txt_f="6219">1</offsets></xref><offsets xml_i="12934" xml_f="13124" txt_i="6219" txt_f="6409">). At the termination of Syst-Eur1 there had been 282 deaths (6.0%), while 124 patients (2.6%) without any report within the year before the trial stopped were counted as lost to follow-up [</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="13155" xml_f="13156" txt_i="6409" txt_f="6410">2</offsets></xref><offsets xml_i="13163" xml_f="13721" txt_i="6410" txt_f="6968">]. These patients were not, therefore, eligible for further follow-up in Syst-Eur2. Furthermore, on February 14,1997, 502 patients (10.6%) had already proceeded to non-supervised follow-up. Of the remaining 3787 patients who were eligible for further follow-up in Syst-Eur2, 3516 (92.8%) participated. On June 15, 2000, 3021 of the 3516 patients enrolled in Syst-Eur2, were still in follow-up, 277 had proceeded to non-supervised follow-up and 158 had died. Sixty patients without any report within the last 18 months were counted as lost to follow-up (Fig. </offsets><xref ref-type="fig" rid="F1"><offsets xml_i="13751" xml_f="13752" txt_i="6968" txt_f="6969">1</offsets></xref><offsets xml_i="13759" xml_f="13901" txt_i="6969" txt_f="7111">). The median follow-up in Syst-Eur2 was 37 months (range 0.3–40 months). The number of patient-years of follow-up in Syst-Eur2 totalled 9988.</offsets></p><fig position="float" id="F1"><label><offsets xml_i="13942" xml_f="13950" txt_i="7112" txt_f="7120">Figure 1</offsets></label><caption><p><offsets xml_i="13970" xml_f="14303" txt_i="7120" txt_f="7453">Profile of patients in the Syst-Eur study. Patients without any report within the last year were classified as lost-to-follow-up in Syst-Eur 1. Patients without any report within the last 18 months were counted as lost to follow-up in Syst-Eur 2. DB, double-blind; NSOF, non-supervised open follow-up; SOF, supervised open follow-up.</offsets></p></caption><graphic xlink:href="cvm-2-6-298-1"></graphic></fig></sec><sec><title><offsets xml_i="14387" xml_f="14410" txt_i="7455" txt_f="7478">Patient characteristics</offsets></title><p><offsets xml_i="14421" xml_f="14427" txt_i="7479" txt_f="7485">Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="14459" xml_f="14460" txt_i="7485" txt_f="7486">1</offsets></xref><offsets xml_i="14467" xml_f="15119" txt_i="7486" txt_f="8138"> presents the characteristics of the 3516 patients at entry into Syst-Eur1 and at baseline into Syst-Eur2. At randomisation, patients in the placebo and active-treatment groups were similar for the distribution of sex, age, BP, pulse rate, body-mass index, serum cholesterol, the use of tobacco and alcohol, and previous cardiovascular complications. Median follow-up in Syst-Eur1 was 1.7 years. At entry into Syst-Eur2 the 2340 women and 1176 men were, on average, 71.2 ± 6.3 years old. As expected, BP at entry into Syst-Eur2 was higher in the former placebo group as compared with the former active-treatment group. Body-mass index (0.23 ± 1.56 kg/m</offsets><sup><offsets xml_i="15124" xml_f="15125" txt_i="8138" txt_f="8139">2</offsets></sup><offsets xml_i="15131" xml_f="15191" txt_i="8139" txt_f="8199">) and total cholesterol (0.17 ± 0.91 mmol/l) had decreased (</offsets><italic><offsets xml_i="15199" xml_f="15200" txt_i="8199" txt_f="8200">P</offsets></italic><offsets xml_i="15209" xml_f="15650" txt_i="8200" txt_f="8638"> &lt; 0.001) during Syst-Eur1, but to a similar extent in the placebo and active-treatment groups. A total of 85 patients stopped smoking and 15 started smoking during Syst-Eur1. Only 38 patients had experienced a nonfatal stroke during Syst-Eur1 and 25 had a nonfatal myocardial infarction. A total of 359 (10.2%) patients had diabetes mellitus at randomisation and another 81 patients (2.3 %) developed diabetes during the Syst-Eur1 trial.</offsets></p><table-wrap position="float" id="T1"><label><offsets xml_i="15698" xml_f="15705" txt_i="8639" txt_f="8646">Table 1</offsets></label><caption><p><offsets xml_i="15725" xml_f="15799" txt_i="8646" txt_f="8720">Patient characteristics at baseline and at the end of the Syst-Eur 1 trial</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="center" colspan="2"><offsets xml_i="15901" xml_f="15920" txt_i="8722" txt_f="8741">Baseline Syst-Eur 1</offsets></td><td align="center" colspan="3"><offsets xml_i="15956" xml_f="15975" txt_i="8742" txt_f="8761">Baseline Syst-Eur 2</offsets></td></tr><tr><td></td><td colspan="2"><hr></hr></td><td colspan="3"><hr></hr></td></tr><tr><td align="left"><offsets xml_i="16084" xml_f="16098" txt_i="8765" txt_f="8779">Characteristic</offsets></td><td align="center"><offsets xml_i="16122" xml_f="16129" txt_i="8780" txt_f="8787">Placebo</offsets></td><td align="center"><offsets xml_i="16153" xml_f="16159" txt_i="8788" txt_f="8794">Active</offsets></td><td align="center"><offsets xml_i="16183" xml_f="16190" txt_i="8795" txt_f="8802">Placebo</offsets><sup><offsets xml_i="16195" xml_f="16196" txt_i="8802" txt_f="8803">†</offsets></sup></td><td></td><td align="center"><offsets xml_i="16235" xml_f="16241" txt_i="8805" txt_f="8811">Active</offsets><sup><offsets xml_i="16246" xml_f="16247" txt_i="8811" txt_f="8812">†</offsets></sup></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="16299" xml_f="16305" txt_i="8813" txt_f="8819">Number</offsets></td><td align="center"><offsets xml_i="16329" xml_f="16333" txt_i="8820" txt_f="8824">1691</offsets></td><td align="center"><offsets xml_i="16357" xml_f="16361" txt_i="8825" txt_f="8829">1825</offsets></td><td align="center"><offsets xml_i="16385" xml_f="16389" txt_i="8830" txt_f="8834">1691</offsets></td><td></td><td align="center"><offsets xml_i="16422" xml_f="16426" txt_i="8836" txt_f="8840">1825</offsets></td></tr><tr><td align="left"><offsets xml_i="16457" xml_f="16467" txt_i="8841" txt_f="8851">Female sex</offsets></td><td align="center"><offsets xml_i="16491" xml_f="16503" txt_i="8852" txt_f="8864">1121 (66.3%)</offsets></td><td align="center"><offsets xml_i="16527" xml_f="16539" txt_i="8865" txt_f="8877">1219 (66.8%)</offsets></td><td align="center"><offsets xml_i="16563" xml_f="16575" txt_i="8878" txt_f="8890">1121 (66.3%)</offsets></td><td></td><td align="center"><offsets xml_i="16608" xml_f="16620" txt_i="8892" txt_f="8904">1219 (66.8%)</offsets></td></tr><tr><td align="left"><offsets xml_i="16651" xml_f="16662" txt_i="8905" txt_f="8916">Age (years)</offsets></td><td align="center"><offsets xml_i="16686" xml_f="16696" txt_i="8917" txt_f="8927">69.0 ± 6.0</offsets></td><td align="center"><offsets xml_i="16720" xml_f="16730" txt_i="8928" txt_f="8938">69.0 ± 5.8</offsets></td><td align="center"><offsets xml_i="16754" xml_f="16764" txt_i="8939" txt_f="8949">71.1 ± 6.4</offsets><sup><offsets xml_i="16769" xml_f="16771" txt_i="8949" txt_f="8951">++</offsets></sup></td><td></td><td align="center"><offsets xml_i="16810" xml_f="16820" txt_i="8953" txt_f="8963">71.2 ± 6.3</offsets><sup><offsets xml_i="16825" xml_f="16827" txt_i="8963" txt_f="8965">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="16864" xml_f="16902" txt_i="8966" txt_f="9004">Sitting systolic blood pressure (mmHg)</offsets></td><td align="center"><offsets xml_i="16926" xml_f="16937" txt_i="9005" txt_f="9016">173.4 ± 9.5</offsets></td><td align="center"><offsets xml_i="16961" xml_f="16972" txt_i="9017" txt_f="9028">173.3 ± 9.4</offsets></td><td align="center"><offsets xml_i="16996" xml_f="17008" txt_i="9029" txt_f="9041">160.4 ± 16.2</offsets><sup><offsets xml_i="17013" xml_f="17015" txt_i="9041" txt_f="9043">++</offsets></sup></td><td align="center"><sup><offsets xml_i="17050" xml_f="17053" txt_i="9044" txt_f="9047">***</offsets></sup></td><td align="center"><offsets xml_i="17083" xml_f="17095" txt_i="9048" txt_f="9060">151.0 ± 14.6</offsets><sup><offsets xml_i="17100" xml_f="17102" txt_i="9060" txt_f="9062">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="17139" xml_f="17178" txt_i="9063" txt_f="9102">Sitting diastolic blood pressure (mmHg)</offsets></td><td align="center"><offsets xml_i="17202" xml_f="17212" txt_i="9103" txt_f="9113">85.6 ± 5.7</offsets></td><td align="center"><offsets xml_i="17236" xml_f="17246" txt_i="9114" txt_f="9124">85.7 ± 5.7</offsets></td><td align="center"><offsets xml_i="17270" xml_f="17280" txt_i="9125" txt_f="9135">83.4 ± 7.7</offsets><sup><offsets xml_i="17285" xml_f="17287" txt_i="9135" txt_f="9137">++</offsets></sup></td><td align="center"><sup><offsets xml_i="17322" xml_f="17325" txt_i="9138" txt_f="9141">***</offsets></sup></td><td align="center"><offsets xml_i="17355" xml_f="17365" txt_i="9142" txt_f="9152">79.6 ± 7.8</offsets><sup><offsets xml_i="17370" xml_f="17372" txt_i="9152" txt_f="9154">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="17409" xml_f="17446" txt_i="9155" txt_f="9192">Sitting heart rate (beats per minute)</offsets></td><td align="center"><offsets xml_i="17470" xml_f="17480" txt_i="9193" txt_f="9203">72.8 ± 8.0</offsets></td><td align="center"><offsets xml_i="17504" xml_f="17514" txt_i="9204" txt_f="9214">72.8 ± 7.9</offsets></td><td align="center"><offsets xml_i="17538" xml_f="17548" txt_i="9215" txt_f="9225">72.5 ± 9.1</offsets></td><td align="center"><sup><offsets xml_i="17577" xml_f="17578" txt_i="9226" txt_f="9227">*</offsets></sup></td><td align="center"><offsets xml_i="17608" xml_f="17618" txt_i="9228" txt_f="9238">73.1 ± 8.9</offsets></td></tr><tr><td align="left"><offsets xml_i="17649" xml_f="17688" txt_i="9239" txt_f="9278">Standing systolic blood pressure (mmHg)</offsets></td><td align="center"><offsets xml_i="17712" xml_f="17724" txt_i="9279" txt_f="9291">168.3 ± 11.5</offsets></td><td align="center"><offsets xml_i="17748" xml_f="17760" txt_i="9292" txt_f="9304">167.9 ± 11.9</offsets></td><td align="center"><offsets xml_i="17784" xml_f="17796" txt_i="9305" txt_f="9317">157.6 ± 16.6</offsets><sup><offsets xml_i="17801" xml_f="17803" txt_i="9317" txt_f="9319">++</offsets></sup></td><td align="center"><sup><offsets xml_i="17838" xml_f="17841" txt_i="9320" txt_f="9323">***</offsets></sup></td><td align="center"><offsets xml_i="17871" xml_f="17883" txt_i="9324" txt_f="9336">148.2 ± 15.5</offsets><sup><offsets xml_i="17888" xml_f="17890" txt_i="9336" txt_f="9338">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="17927" xml_f="17967" txt_i="9339" txt_f="9379">Standing diastolic blood pressure (mmHg)</offsets></td><td align="center"><offsets xml_i="17991" xml_f="18001" txt_i="9380" txt_f="9390">87.6 ± 7.6</offsets></td><td align="center"><offsets xml_i="18025" xml_f="18035" txt_i="9391" txt_f="9401">87.6 ± 7.6</offsets></td><td align="center"><offsets xml_i="18059" xml_f="18069" txt_i="9402" txt_f="9412">85.1 ± 9.2</offsets><sup><offsets xml_i="18074" xml_f="18076" txt_i="9412" txt_f="9414">++</offsets></sup></td><td align="center"><sup><offsets xml_i="18111" xml_f="18114" txt_i="9415" txt_f="9418">***</offsets></sup></td><td align="center"><offsets xml_i="18144" xml_f="18154" txt_i="9419" txt_f="9429">81.6 ± 8.9</offsets><sup><offsets xml_i="18159" xml_f="18161" txt_i="9429" txt_f="9431">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="18198" xml_f="18219" txt_i="9432" txt_f="9453">Body-mass index (kg/m</offsets><sup><offsets xml_i="18224" xml_f="18225" txt_i="9453" txt_f="9454">2</offsets></sup><offsets xml_i="18231" xml_f="18232" txt_i="9454" txt_f="9455">)</offsets></td><td align="center"><offsets xml_i="18256" xml_f="18266" txt_i="9456" txt_f="9466">27.3 ± 4.0</offsets></td><td align="center"><offsets xml_i="18290" xml_f="18300" txt_i="9467" txt_f="9477">27.3 ± 4.2</offsets></td><td align="center"><offsets xml_i="18324" xml_f="18334" txt_i="9478" txt_f="9488">27.0 ± 4.0</offsets><sup><offsets xml_i="18339" xml_f="18341" txt_i="9488" txt_f="9490">++</offsets></sup></td><td></td><td align="center"><offsets xml_i="18380" xml_f="18390" txt_i="9492" txt_f="9502">27.1 ± 4.2</offsets><sup><offsets xml_i="18395" xml_f="18397" txt_i="9502" txt_f="9504">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="18434" xml_f="18460" txt_i="9505" txt_f="9531">Total cholesterol (mmol/l)</offsets></td><td align="center"><offsets xml_i="18484" xml_f="18493" txt_i="9532" txt_f="9541">6.0 ± 1.2</offsets></td><td align="center"><offsets xml_i="18517" xml_f="18526" txt_i="9542" txt_f="9551">6.0 ± 1.2</offsets></td><td align="center"><offsets xml_i="18550" xml_f="18559" txt_i="9552" txt_f="9561">5.9 ± 1.1</offsets><sup><offsets xml_i="18564" xml_f="18566" txt_i="9561" txt_f="9563">++</offsets></sup></td><td></td><td align="center"><offsets xml_i="18605" xml_f="18614" txt_i="9565" txt_f="9574">5.8 ± 1.1</offsets><sup><offsets xml_i="18619" xml_f="18621" txt_i="9574" txt_f="9576">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="18658" xml_f="18703" txt_i="9577" txt_f="9622">High-density-lipoprotein cholesterol (mmol/l)</offsets></td><td align="center"><offsets xml_i="18727" xml_f="18738" txt_i="9623" txt_f="9634">1.40 ± 0.46</offsets></td><td align="center"><offsets xml_i="18762" xml_f="18773" txt_i="9635" txt_f="9646">1.42 ± 0.48</offsets></td><td align="center"><offsets xml_i="18797" xml_f="18808" txt_i="9647" txt_f="9658">1.36 ± 0.40</offsets><sup><offsets xml_i="18813" xml_f="18814" txt_i="9658" txt_f="9659">+</offsets></sup></td><td align="center"><sup><offsets xml_i="18849" xml_f="18850" txt_i="9660" txt_f="9661">*</offsets></sup></td><td align="center"><offsets xml_i="18880" xml_f="18891" txt_i="9662" txt_f="9673">1.40 ± 0.47</offsets></td></tr><tr><td align="left"><offsets xml_i="18922" xml_f="18939" txt_i="9674" txt_f="9691">History of stroke</offsets></td><td align="center"><offsets xml_i="18963" xml_f="18972" txt_i="9692" txt_f="9701">18 (1.1%)</offsets></td><td align="center"><offsets xml_i="18996" xml_f="19005" txt_i="9702" txt_f="9711">20 (1.1%)</offsets></td><td align="center"><offsets xml_i="19029" xml_f="19038" txt_i="9712" txt_f="9721">39 (2.3%)</offsets><sup><offsets xml_i="19043" xml_f="19045" txt_i="9721" txt_f="9723">++</offsets></sup></td><td></td><td align="center"><offsets xml_i="19084" xml_f="19093" txt_i="9725" txt_f="9734">34 (1.9%)</offsets><sup><offsets xml_i="19098" xml_f="19100" txt_i="9734" txt_f="9736">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="19137" xml_f="19169" txt_i="9737" txt_f="9769">History of myocardial infarction</offsets></td><td align="center"><offsets xml_i="19193" xml_f="19202" txt_i="9770" txt_f="9779">61 (3.6%)</offsets></td><td align="center"><offsets xml_i="19226" xml_f="19235" txt_i="9780" txt_f="9789">62 (3.4%)</offsets></td><td align="center"><offsets xml_i="19259" xml_f="19268" txt_i="9790" txt_f="9799">73 (4.3%)</offsets><sup><offsets xml_i="19273" xml_f="19275" txt_i="9799" txt_f="9801">++</offsets></sup></td><td align="center"><sup><offsets xml_i="19310" xml_f="19312" txt_i="9802" txt_f="9804">**</offsets></sup></td><td align="center"><offsets xml_i="19342" xml_f="19351" txt_i="9805" txt_f="9814">71 (3.9%)</offsets><sup><offsets xml_i="19356" xml_f="19358" txt_i="9814" txt_f="9816">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="19395" xml_f="19412" txt_i="9817" txt_f="9834">Diabetes mellitus</offsets></td><td align="center"><offsets xml_i="19436" xml_f="19447" txt_i="9835" txt_f="9846">170 (10.1%)</offsets></td><td align="center"><offsets xml_i="19471" xml_f="19482" txt_i="9847" txt_f="9858">189 (10.4%)</offsets></td><td align="center"><offsets xml_i="19506" xml_f="19517" txt_i="9859" txt_f="9870">205 (12.1%)</offsets><sup><offsets xml_i="19522" xml_f="19524" txt_i="9870" txt_f="9872">++</offsets></sup></td><td></td><td align="center"><offsets xml_i="19563" xml_f="19574" txt_i="9874" txt_f="9885">235 (12.9%)</offsets><sup><offsets xml_i="19579" xml_f="19581" txt_i="9885" txt_f="9887">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="19618" xml_f="19633" txt_i="9888" txt_f="9903">Current smokers</offsets></td><td align="center"><offsets xml_i="19657" xml_f="19667" txt_i="9904" txt_f="9914">106 (6.3%)</offsets></td><td align="center"><offsets xml_i="19691" xml_f="19701" txt_i="9915" txt_f="9925">121 (6.6%)</offsets></td><td align="center"><offsets xml_i="19725" xml_f="19734" txt_i="9926" txt_f="9935">71 (4.2%)</offsets><sup><offsets xml_i="19739" xml_f="19741" txt_i="9935" txt_f="9937">++</offsets></sup></td><td></td><td align="center"><offsets xml_i="19780" xml_f="19789" txt_i="9939" txt_f="9948">86 (4.7%)</offsets><sup><offsets xml_i="19794" xml_f="19796" txt_i="9948" txt_f="9950">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="19833" xml_f="19856" txt_i="9951" txt_f="9974">Abstaining from alcohol</offsets></td><td align="center"><offsets xml_i="19880" xml_f="19892" txt_i="9975" txt_f="9987">1227 (72.6%)</offsets></td><td align="center"><offsets xml_i="19916" xml_f="19928" txt_i="9988" txt_f="10000">1311 (71.9%)</offsets></td><td align="center"><offsets xml_i="19952" xml_f="19964" txt_i="10001" txt_f="10013">1324 (78.3%)</offsets><sup><offsets xml_i="19969" xml_f="19971" txt_i="10013" txt_f="10015">++</offsets></sup></td><td></td><td align="center"><offsets xml_i="20010" xml_f="20022" txt_i="10017" txt_f="10029">1388 (76.1%)</offsets><sup><offsets xml_i="20027" xml_f="20029" txt_i="10029" txt_f="10031">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="20066" xml_f="20092" txt_i="10032" txt_f="10055">&lt;1 unit alcohol per day</offsets></td><td align="center"><offsets xml_i="20116" xml_f="20127" txt_i="10056" txt_f="10067">282 (16.7%)</offsets></td><td align="center"><offsets xml_i="20151" xml_f="20162" txt_i="10068" txt_f="10079">337 (18.4%)</offsets></td><td align="center"><offsets xml_i="20186" xml_f="20197" txt_i="10080" txt_f="10091">225 (13.3%)</offsets><sup><offsets xml_i="20202" xml_f="20204" txt_i="10091" txt_f="10093">++</offsets></sup></td><td></td><td align="center"><offsets xml_i="20243" xml_f="20254" txt_i="10095" txt_f="10106">261 (14.3%)</offsets><sup><offsets xml_i="20259" xml_f="20261" txt_i="10106" txt_f="10108">++</offsets></sup></td></tr><tr><td align="left"><offsets xml_i="20298" xml_f="20322" txt_i="10109" txt_f="10133">≥ 1 unit alcohol per day</offsets></td><td align="center"><offsets xml_i="20346" xml_f="20357" txt_i="10134" txt_f="10145">181 (10.7%)</offsets></td><td align="center"><offsets xml_i="20381" xml_f="20391" txt_i="10146" txt_f="10156">176 (9.7%)</offsets></td><td align="center"><offsets xml_i="20415" xml_f="20425" txt_i="10157" txt_f="10167">142 (8.4%)</offsets><sup><offsets xml_i="20430" xml_f="20432" txt_i="10167" txt_f="10169">++</offsets></sup></td><td></td><td align="center"><offsets xml_i="20471" xml_f="20481" txt_i="10171" txt_f="10181">175 (9.6%)</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="20527" xml_f="20584" txt_i="10182" txt_f="10239">Values are given as mean ± SD or number of patients (%). </offsets><sup><offsets xml_i="20589" xml_f="20590" txt_i="10239" txt_f="10240">†</offsets></sup><offsets xml_i="20596" xml_f="20712" txt_i="10240" txt_f="10356"> Indicates patients formerly randomised to placebo and active treatment. Significance of between-group differences: </offsets><sup><offsets xml_i="20717" xml_f="20718" txt_i="10356" txt_f="10357">*</offsets></sup><italic><offsets xml_i="20732" xml_f="20733" txt_i="10357" txt_f="10358">P</offsets></italic><offsets xml_i="20742" xml_f="20754" txt_i="10358" txt_f="10367"> &lt; 0.05; </offsets><sup><offsets xml_i="20759" xml_f="20761" txt_i="10367" txt_f="10369">**</offsets></sup><italic><offsets xml_i="20775" xml_f="20776" txt_i="10369" txt_f="10370">P</offsets></italic><offsets xml_i="20785" xml_f="20797" txt_i="10370" txt_f="10379"> &lt; 0.01; </offsets><sup><offsets xml_i="20802" xml_f="20805" txt_i="10379" txt_f="10382">***</offsets></sup><italic><offsets xml_i="20819" xml_f="20820" txt_i="10382" txt_f="10383">P</offsets></italic><offsets xml_i="20829" xml_f="20880" txt_i="10383" txt_f="10431"> &lt; 0.001. Significance of within-group changes: </offsets><sup><offsets xml_i="20885" xml_f="20886" txt_i="10431" txt_f="10432">+</offsets></sup><italic><offsets xml_i="20900" xml_f="20901" txt_i="10432" txt_f="10433">P</offsets></italic><offsets xml_i="20910" xml_f="20922" txt_i="10433" txt_f="10442"> &lt; 0.01; </offsets><sup><offsets xml_i="20927" xml_f="20929" txt_i="10442" txt_f="10444">++</offsets></sup><italic><offsets xml_i="20943" xml_f="20944" txt_i="10444" txt_f="10445">P</offsets></italic><offsets xml_i="20953" xml_f="20965" txt_i="10445" txt_f="10454"> &lt; 0.001.</offsets></p></table-wrap-foot></table-wrap></sec><sec><title><offsets xml_i="21018" xml_f="21027" txt_i="10456" txt_f="10465">Treatment</offsets></title><p><offsets xml_i="21038" xml_f="21093" txt_i="10466" txt_f="10521">At the end of Syst-Eur1, significantly fewer patients (</offsets><italic><offsets xml_i="21101" xml_f="21102" txt_i="10521" txt_f="10522">P</offsets></italic><offsets xml_i="21111" xml_f="21277" txt_i="10522" txt_f="10685"> &lt; 0.001) in the active treatment group than in the control group had proceeded to combined treatment with various double-blind medications. Also, fewer patients (</offsets><italic><offsets xml_i="21285" xml_f="21286" txt_i="10685" txt_f="10686">P</offsets></italic><offsets xml_i="21295" xml_f="21369" txt_i="10686" txt_f="10757"> &lt; 0.001) randomised to active treatment were in open follow-up (Table </offsets><xref ref-type="table" rid="T2"><offsets xml_i="21401" xml_f="21402" txt_i="10757" txt_f="10758">2</offsets></xref><offsets xml_i="21409" xml_f="21538" txt_i="10758" txt_f="10887">). At the last visit in Syst-Eur1, 1514 (83.0%) patients of the active treatment group took nitrendipine, either in monotherapy (</offsets><italic><offsets xml_i="21546" xml_f="21547" txt_i="10887" txt_f="10888">n</offsets></italic><offsets xml_i="21556" xml_f="21633" txt_i="10888" txt_f="10965"> = 1065; 58.4%) or in combination with enalapril and/or hydrochlorothiazide (</offsets><italic><offsets xml_i="21641" xml_f="21642" txt_i="10965" txt_f="10966">n</offsets></italic><offsets xml_i="21651" xml_f="21768" txt_i="10966" txt_f="11083"> = 449; 24.6%). The average daily doses of the active double-blind medications were 28.1 ± 12.1 mg for nitrendipine (</offsets><italic><offsets xml_i="21776" xml_f="21777" txt_i="11083" txt_f="11084">n</offsets></italic><offsets xml_i="21786" xml_f="21825" txt_i="11084" txt_f="11123"> = 1514), 13.6 ± 6.1 mg for enalapril (</offsets><italic><offsets xml_i="21833" xml_f="21834" txt_i="11123" txt_f="11124">n</offsets></italic><offsets xml_i="21843" xml_f="21895" txt_i="11124" txt_f="11176"> = 557), and 21.4 ± 6.8 mg for hydrochlorothiazide (</offsets><italic><offsets xml_i="21903" xml_f="21904" txt_i="11176" txt_f="11177">n</offsets></italic><offsets xml_i="21913" xml_f="22036" txt_i="11177" txt_f="11300"> = 220). Of the 235 diabetic patients randomised to active treatment, 197 (83.8%) took nitrendipine either in monotherapy (</offsets><italic><offsets xml_i="22044" xml_f="22045" txt_i="11300" txt_f="11301">n</offsets></italic><offsets xml_i="22054" xml_f="22131" txt_i="11301" txt_f="11378"> = 136; 57.9%) or in combination with the second and/or the third line drug (</offsets><italic><offsets xml_i="22139" xml_f="22140" txt_i="11378" txt_f="11379">n</offsets></italic><offsets xml_i="22149" xml_f="22163" txt_i="11379" txt_f="11393"> = 61; 26.0%).</offsets></p><table-wrap position="float" id="T2"><label><offsets xml_i="22211" xml_f="22218" txt_i="11394" txt_f="11401">Table 2</offsets></label><caption><p><offsets xml_i="22238" xml_f="22310" txt_i="11401" txt_f="11473">Treatment status at the termination of the double-blind Syst-Eur 1 trial</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td></td><td align="center"><offsets xml_i="22409" xml_f="22415" txt_i="11476" txt_f="11482">Active</offsets></td></tr><tr><td></td><td align="center"><offsets xml_i="22457" xml_f="22464" txt_i="11484" txt_f="11491">Placebo</offsets><sup><offsets xml_i="22469" xml_f="22470" txt_i="11491" txt_f="11492">*</offsets></sup></td><td align="center"><offsets xml_i="22500" xml_f="22509" txt_i="11493" txt_f="11502">treatment</offsets><sup><offsets xml_i="22514" xml_f="22515" txt_i="11502" txt_f="11503">*</offsets></sup></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="22567" xml_f="22579" txt_i="11504" txt_f="11516">Total number</offsets></td><td align="center"><offsets xml_i="22603" xml_f="22607" txt_i="11517" txt_f="11521">1691</offsets></td><td align="center"><offsets xml_i="22631" xml_f="22635" txt_i="11522" txt_f="11526">1825</offsets></td></tr><tr><td align="left"><offsets xml_i="22666" xml_f="22697" txt_i="11527" txt_f="11558">Still in double-blind follow-up</offsets></td><td align="center"><offsets xml_i="22721" xml_f="22731" txt_i="11559" txt_f="11569">1487 (88%)</offsets></td><td align="center"><offsets xml_i="22755" xml_f="22765" txt_i="11570" txt_f="11580">1718 (94%)</offsets></td></tr><tr><td align="left"><offsets xml_i="22796" xml_f="22811" txt_i="11581" txt_f="11596"> No study drugs</offsets></td><td align="center"><offsets xml_i="22835" xml_f="22842" txt_i="11597" txt_f="11604">25 (1%)</offsets></td><td align="center"><offsets xml_i="22866" xml_f="22873" txt_i="11605" txt_f="11612">28 (2%)</offsets></td></tr><tr><td align="left"><offsets xml_i="22904" xml_f="22930" txt_i="11613" txt_f="11639"> Nitrendipine/placebo only</offsets></td><td align="center"><offsets xml_i="22954" xml_f="22963" txt_i="11640" txt_f="11649">665 (39%)</offsets></td><td align="center"><offsets xml_i="22987" xml_f="22997" txt_i="11650" txt_f="11660">1065 (58%)</offsets></td></tr><tr><td align="left"><offsets xml_i="23028" xml_f="23056" txt_i="11661" txt_f="11689"> Study medication other than</offsets></td><td align="center"><offsets xml_i="23080" xml_f="23089" txt_i="11690" txt_f="11699">797 (47%)</offsets></td><td align="center"><offsets xml_i="23113" xml_f="23122" txt_i="11700" txt_f="11709">625 (34%)</offsets></td></tr><tr><td align="left"><offsets xml_i="23153" xml_f="23167" txt_i="11710" txt_f="11724">  nitrendipine</offsets></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="23216" xml_f="23228" txt_i="11727" txt_f="11739"> Drugs taken</offsets><sup><offsets xml_i="23233" xml_f="23234" txt_i="11739" txt_f="11740">†</offsets></sup></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="23289" xml_f="23311" txt_i="11743" txt_f="11765">  Nitrendipine/placebo</offsets></td><td align="center"><offsets xml_i="23335" xml_f="23345" txt_i="11766" txt_f="11776">1396 (83%)</offsets></td><td align="center"><offsets xml_i="23369" xml_f="23379" txt_i="11777" txt_f="11787">1514 (83%)</offsets></td></tr><tr><td align="left"><offsets xml_i="23410" xml_f="23429" txt_i="11788" txt_f="11807">  Enalapril/placebo</offsets></td><td align="center"><offsets xml_i="23453" xml_f="23462" txt_i="11808" txt_f="11817">757 (45%)</offsets></td><td align="center"><offsets xml_i="23486" xml_f="23495" txt_i="11818" txt_f="11827">557 (31%)</offsets></td></tr><tr><td align="left"><offsets xml_i="23526" xml_f="23555" txt_i="11828" txt_f="11857">  Hydrochlorothiazide/placebo</offsets></td><td align="center"><offsets xml_i="23579" xml_f="23588" txt_i="11858" txt_f="11867">399 (24%)</offsets></td><td align="center"><offsets xml_i="23612" xml_f="23621" txt_i="11868" txt_f="11877">220 (12%)</offsets></td></tr><tr><td align="left"><offsets xml_i="23652" xml_f="23681" txt_i="11878" txt_f="11907">  Open-label antihypertensive</offsets></td><td align="center"><offsets xml_i="23705" xml_f="23712" txt_i="11908" txt_f="11915">20 (1%)</offsets></td><td align="center"><offsets xml_i="23736" xml_f="23743" txt_i="11916" txt_f="11923">13 (1%)</offsets></td></tr><tr><td align="left"><offsets xml_i="23774" xml_f="23781" txt_i="11924" txt_f="11931">  drugs</offsets><sup><offsets xml_i="23786" xml_f="23787" txt_i="11931" txt_f="11932">‡</offsets></sup></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="23842" xml_f="23867" txt_i="11935" txt_f="11960">Supervised open follow-up</offsets></td><td align="center"><offsets xml_i="23891" xml_f="23900" txt_i="11961" txt_f="11970">204 (12%)</offsets></td><td align="center"><offsets xml_i="23924" xml_f="23932" txt_i="11971" txt_f="11979">107 (6%)</offsets></td></tr><tr><td align="left"><offsets xml_i="23963" xml_f="23989" txt_i="11980" txt_f="12006"> No antihypertensive drugs</offsets></td><td align="center"><offsets xml_i="24013" xml_f="24020" txt_i="12007" txt_f="12014">43 (3%)</offsets></td><td align="center"><offsets xml_i="24044" xml_f="24051" txt_i="12015" txt_f="12022">25 (1%)</offsets></td></tr><tr><td align="left"><offsets xml_i="24082" xml_f="24116" txt_i="12023" txt_f="12057"> Open-label antihypertensive drugs</offsets></td><td align="center"><offsets xml_i="24140" xml_f="24148" txt_i="12058" txt_f="12066">142 (8%)</offsets></td><td align="center"><offsets xml_i="24172" xml_f="24179" txt_i="12067" txt_f="12074">74 (4%)</offsets></td></tr><tr><td align="left"><offsets xml_i="24210" xml_f="24228" txt_i="12075" txt_f="12093"> Treatment unknown</offsets></td><td align="center"><offsets xml_i="24252" xml_f="24259" txt_i="12094" txt_f="12101">19 (1%)</offsets></td><td align="center"><offsets xml_i="24283" xml_f="24289" txt_i="12102" txt_f="12108">8 (0%)</offsets></td></tr></tbody></table><table-wrap-foot><p><sup><offsets xml_i="24340" xml_f="24341" txt_i="12109" txt_f="12110">*</offsets></sup><offsets xml_i="24347" xml_f="24418" txt_i="12110" txt_f="12181">Indicates patients formerly randomised to placebo or active treatment. </offsets><sup><offsets xml_i="24423" xml_f="24424" txt_i="12181" txt_f="12182">†</offsets></sup><offsets xml_i="24430" xml_f="24503" txt_i="12182" txt_f="12255">Because many patients were on combined treatment, numbers do not add up. </offsets><sup><offsets xml_i="24508" xml_f="24509" txt_i="12255" txt_f="12256">‡</offsets></sup><offsets xml_i="24515" xml_f="24683" txt_i="12256" txt_f="12424">To bridge medical emergencies without having to break the code, antihypertensive drugs could be prescribed during the double-blind trial for up to 3 consecutive months.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="24721" xml_f="24923" txt_i="12425" txt_f="12627">At the last visit in Syst-Eur2, the number of patients proceeding to combined treatment with the various study drugs was similar in the former placebo (40.6%) and active-treatment (43.8%) groups (Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="24955" xml_f="24956" txt_i="12627" txt_f="12628">3</offsets></xref><offsets xml_i="24963" xml_f="25076" txt_i="12628" txt_f="12741">). Of the 1691 patients previously randomised to placebo, 1194 (70.6%) took nitrendipine, either in monotherapy (</offsets><italic><offsets xml_i="25084" xml_f="25085" txt_i="12741" txt_f="12742">n</offsets></italic><offsets xml_i="25094" xml_f="25206" txt_i="12742" txt_f="12854"> = 596; 35.2%) or in combination with enalapril and/or hydrochlorothiazide and/or other antihypertensive drugs (</offsets><italic><offsets xml_i="25214" xml_f="25215" txt_i="12854" txt_f="12855">n</offsets></italic><offsets xml_i="25224" xml_f="25348" txt_i="12855" txt_f="12979"> = 598; 35.4%). Among the 1825 patients of the former active-treatment group, 1328 (72.8%) took nitrendipine, either alone (</offsets><italic><offsets xml_i="25356" xml_f="25357" txt_i="12979" txt_f="12980">n</offsets></italic><offsets xml_i="25366" xml_f="25418" txt_i="12980" txt_f="13032"> = 676; 37.0%), or in combination with other drugs (</offsets><italic><offsets xml_i="25426" xml_f="25427" txt_i="13032" txt_f="13033">n</offsets></italic><offsets xml_i="25436" xml_f="25458" txt_i="13033" txt_f="13055"> = 652; 35.7%) (Table </offsets><xref ref-type="table" rid="T3"><offsets xml_i="25490" xml_f="25491" txt_i="13055" txt_f="13056">3</offsets></xref><offsets xml_i="25498" xml_f="25641" txt_i="13056" txt_f="13199">). At the last available visit, the average daily doses of the study drugs in the patients formerly randomised to placebo were 31.0 ± 11.1 mg (</offsets><italic><offsets xml_i="25649" xml_f="25650" txt_i="13199" txt_f="13200">n</offsets></italic><offsets xml_i="25659" xml_f="25715" txt_i="13200" txt_f="13256"> = 1194) for nitrendipine, 15.1 ± 5.7 mg for enalapril (</offsets><italic><offsets xml_i="25723" xml_f="25724" txt_i="13256" txt_f="13257">n</offsets></italic><offsets xml_i="25733" xml_f="25761" txt_i="13257" txt_f="13285"> = 693), and 24.1 ± 9.7 mg (</offsets><italic><offsets xml_i="25769" xml_f="25770" txt_i="13285" txt_f="13286">n</offsets></italic><offsets xml_i="25779" xml_f="25905" txt_i="13286" txt_f="13412"> = 326) for hydro-chlorothiazide. In the patients previously randomised to active treatment, these doses were 31.2 ± 11.2 mg (</offsets><italic><offsets xml_i="25913" xml_f="25914" txt_i="13412" txt_f="13413">n</offsets></italic><offsets xml_i="25923" xml_f="25948" txt_i="13413" txt_f="13438"> = 1328), 15.3 ± 5.8 mg (</offsets><italic><offsets xml_i="25956" xml_f="25957" txt_i="13438" txt_f="13439">n</offsets></italic><offsets xml_i="25966" xml_f="25994" txt_i="13439" txt_f="13467"> = 823), and 23.7 ± 8.2 mg (</offsets><italic><offsets xml_i="26002" xml_f="26003" txt_i="13467" txt_f="13468">n</offsets></italic><offsets xml_i="26012" xml_f="26033" txt_i="13468" txt_f="13489"> = 424) respectively.</offsets></p><table-wrap position="float" id="T3"><label><offsets xml_i="26081" xml_f="26088" txt_i="13490" txt_f="13497">Table 3</offsets></label><caption><p><offsets xml_i="26108" xml_f="26157" txt_i="13497" txt_f="13546">Antihypertensive drug treatment during Syst-Eur 2</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left" colspan="4"><offsets xml_i="26257" xml_f="26287" txt_i="13548" txt_f="13578">Formerly randomised to placebo</offsets></td><td align="left" colspan="4"><offsets xml_i="26321" xml_f="26360" txt_i="13579" txt_f="13618">Formerly randomised to active treatment</offsets></td></tr><tr><td></td><td colspan="4"><hr></hr></td><td colspan="4"><hr></hr></td></tr><tr><td></td><td align="left"><offsets xml_i="26478" xml_f="26485" txt_i="13623" txt_f="13630">Month 3</offsets></td><td align="left"><offsets xml_i="26507" xml_f="26513" txt_i="13631" txt_f="13637">Year 1</offsets></td><td align="left"><offsets xml_i="26535" xml_f="26541" txt_i="13638" txt_f="13644">Year 3</offsets></td><td align="left"><offsets xml_i="26563" xml_f="26573" txt_i="13645" txt_f="13655">Last visit</offsets></td><td align="left"><offsets xml_i="26595" xml_f="26602" txt_i="13656" txt_f="13663">Month 3</offsets></td><td align="left"><offsets xml_i="26624" xml_f="26630" txt_i="13664" txt_f="13670">Year 1</offsets></td><td align="left"><offsets xml_i="26652" xml_f="26658" txt_i="13671" txt_f="13677">Year 3</offsets></td><td align="left"><offsets xml_i="26680" xml_f="26690" txt_i="13678" txt_f="13688">Last visit</offsets></td></tr></thead><tbody><tr><td align="left"><offsets xml_i="26736" xml_f="26760" txt_i="13689" txt_f="13713">Total number of patients</offsets></td><td align="left"><offsets xml_i="26782" xml_f="26786" txt_i="13714" txt_f="13718">1086</offsets></td><td align="left"><offsets xml_i="26808" xml_f="26812" txt_i="13719" txt_f="13723">1561</offsets></td><td align="left"><offsets xml_i="26834" xml_f="26838" txt_i="13724" txt_f="13728">1210</offsets></td><td align="left"><offsets xml_i="26860" xml_f="26864" txt_i="13729" txt_f="13733">1691</offsets></td><td align="left"><offsets xml_i="26886" xml_f="26890" txt_i="13734" txt_f="13738">1206</offsets></td><td align="left"><offsets xml_i="26912" xml_f="26916" txt_i="13739" txt_f="13743">1682</offsets></td><td align="left"><offsets xml_i="26938" xml_f="26942" txt_i="13744" txt_f="13748">1291</offsets></td><td align="left"><offsets xml_i="26964" xml_f="26968" txt_i="13749" txt_f="13753">1825</offsets></td></tr><tr><td align="left"><offsets xml_i="26999" xml_f="27010" txt_i="13754" txt_f="13765">On AH drugs</offsets></td><td align="left"><offsets xml_i="27032" xml_f="27041" txt_i="13766" txt_f="13775">966 (89%)</offsets></td><td align="left"><offsets xml_i="27063" xml_f="27073" txt_i="13776" txt_f="13786">1504 (96%)</offsets></td><td align="left"><offsets xml_i="27095" xml_f="27105" txt_i="13787" txt_f="13797">1177 (97%)</offsets></td><td align="left"><offsets xml_i="27127" xml_f="27137" txt_i="13798" txt_f="13808">1605 (95%)</offsets></td><td align="left"><offsets xml_i="27159" xml_f="27169" txt_i="13809" txt_f="13819">1186 (98%)</offsets></td><td align="left"><offsets xml_i="27191" xml_f="27201" txt_i="13820" txt_f="13830">1654 (98%)</offsets></td><td align="left"><offsets xml_i="27223" xml_f="27233" txt_i="13831" txt_f="13841">1267 (98%)</offsets></td><td align="left"><offsets xml_i="27255" xml_f="27265" txt_i="13842" txt_f="13852">1762 (97%)</offsets></td></tr><tr><td align="left"><offsets xml_i="27296" xml_f="27314" txt_i="13853" txt_f="13871"> Only nitrendipine</offsets></td><td align="left"><offsets xml_i="27336" xml_f="27345" txt_i="13872" txt_f="13881">713 (66%)</offsets></td><td align="left"><offsets xml_i="27367" xml_f="27376" txt_i="13882" txt_f="13891">732 (47%)</offsets></td><td align="left"><offsets xml_i="27398" xml_f="27407" txt_i="13892" txt_f="13901">403 (33%)</offsets></td><td align="left"><offsets xml_i="27429" xml_f="27438" txt_i="13902" txt_f="13911">596 (35%)</offsets></td><td align="left"><offsets xml_i="27460" xml_f="27469" txt_i="13912" txt_f="13921">651 (54%)</offsets></td><td align="left"><offsets xml_i="27491" xml_f="27500" txt_i="13922" txt_f="13931">747 (44%)</offsets></td><td align="left"><offsets xml_i="27522" xml_f="27531" txt_i="13932" txt_f="13941">475 (37%)</offsets></td><td align="left"><offsets xml_i="27553" xml_f="27562" txt_i="13942" txt_f="13951">676 (37%)</offsets></td></tr><tr><td align="left"><offsets xml_i="27593" xml_f="27629" txt_i="13952" txt_f="13988"> Study drugs other than nitrendipine</offsets></td><td align="left"><offsets xml_i="27651" xml_f="27660" txt_i="13989" txt_f="13998">127 (12%)</offsets></td><td align="left"><offsets xml_i="27682" xml_f="27691" txt_i="13999" txt_f="14008">547 (35%)</offsets></td><td align="left"><offsets xml_i="27713" xml_f="27722" txt_i="14009" txt_f="14018">546 (45%)</offsets></td><td align="left"><offsets xml_i="27744" xml_f="27753" txt_i="14019" txt_f="14028">687 (41%)</offsets></td><td align="left"><offsets xml_i="27775" xml_f="27784" txt_i="14029" txt_f="14038">466 (39%)</offsets></td><td align="left"><offsets xml_i="27806" xml_f="27815" txt_i="14039" txt_f="14048">738 (44%)</offsets></td><td align="left"><offsets xml_i="27837" xml_f="27846" txt_i="14049" txt_f="14058">599 (46%)</offsets></td><td align="left"><offsets xml_i="27868" xml_f="27877" txt_i="14059" txt_f="14068">799 (44%)</offsets></td></tr><tr><td align="left"><offsets xml_i="27908" xml_f="27929" txt_i="14069" txt_f="14090">  (no other AH drugs)</offsets></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="28032" xml_f="28061" txt_i="14099" txt_f="14128"> Study drugs + other AH drugs</offsets></td><td align="left"><offsets xml_i="28083" xml_f="28090" txt_i="14129" txt_f="14136">19 (2%)</offsets></td><td align="left"><offsets xml_i="28112" xml_f="28119" txt_i="14137" txt_f="14144">82 (5%)</offsets></td><td align="left"><offsets xml_i="28141" xml_f="28150" txt_i="14145" txt_f="14154">118 (10%)</offsets></td><td align="left"><offsets xml_i="28172" xml_f="28180" txt_i="14155" txt_f="14163">145 (9%)</offsets></td><td align="left"><offsets xml_i="28202" xml_f="28209" txt_i="14164" txt_f="14171">14 (1%)</offsets></td><td align="left"><offsets xml_i="28231" xml_f="28238" txt_i="14172" txt_f="14179">69 (4%)</offsets></td><td align="left"><offsets xml_i="28260" xml_f="28268" txt_i="14180" txt_f="14188">120 (9%)</offsets></td><td align="left"><offsets xml_i="28290" xml_f="28298" txt_i="14189" txt_f="14197">155 (8%)</offsets></td></tr><tr><td align="left"><offsets xml_i="28329" xml_f="28349" txt_i="14198" txt_f="14218"> Other AH drugs only</offsets></td><td align="left"><offsets xml_i="28371" xml_f="28380" txt_i="14219" txt_f="14228">107 (10%)</offsets></td><td align="left"><offsets xml_i="28402" xml_f="28410" txt_i="14229" txt_f="14237">143 (9%)</offsets></td><td align="left"><offsets xml_i="28432" xml_f="28440" txt_i="14238" txt_f="14246">110 (9%)</offsets></td><td align="left"><offsets xml_i="28462" xml_f="28471" txt_i="14247" txt_f="14256">177 (10%)</offsets></td><td align="left"><offsets xml_i="28493" xml_f="28500" txt_i="14257" txt_f="14264">55 (5%)</offsets></td><td align="left"><offsets xml_i="28522" xml_f="28530" txt_i="14265" txt_f="14273">100 (6%)</offsets></td><td align="left"><offsets xml_i="28552" xml_f="28559" txt_i="14274" txt_f="14281">73 (5%)</offsets></td><td align="left"><offsets xml_i="28581" xml_f="28589" txt_i="14282" txt_f="14290">132 (7%)</offsets></td></tr><tr><td align="left"><offsets xml_i="28620" xml_f="28631" txt_i="14291" txt_f="14302">Drugs taken</offsets><sup><offsets xml_i="28636" xml_f="28637" txt_i="14302" txt_f="14303">†</offsets></sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><offsets xml_i="28746" xml_f="28759" txt_i="14312" txt_f="14325"> Nitrendipine</offsets></td><td align="left"><offsets xml_i="28781" xml_f="28790" txt_i="14326" txt_f="14335">821 (76%)</offsets></td><td align="left"><offsets xml_i="28812" xml_f="28822" txt_i="14336" txt_f="14346">1186 (76%)</offsets></td><td align="left"><offsets xml_i="28844" xml_f="28853" txt_i="14347" txt_f="14356">883 (73%)</offsets></td><td align="left"><offsets xml_i="28875" xml_f="28885" txt_i="14357" txt_f="14367">1194 (71%)</offsets></td><td align="left"><offsets xml_i="28907" xml_f="28916" txt_i="14368" txt_f="14377">998 (83%)</offsets></td><td align="left"><offsets xml_i="28938" xml_f="28948" txt_i="14378" txt_f="14388">1322 (79%)</offsets></td><td align="left"><offsets xml_i="28970" xml_f="28979" txt_i="14389" txt_f="14398">974 (75%)</offsets></td><td align="left"><offsets xml_i="29001" xml_f="29011" txt_i="14399" txt_f="14409">1328 (73%)</offsets></td></tr><tr><td align="left"><offsets xml_i="29042" xml_f="29052" txt_i="14410" txt_f="14420"> Enalapril</offsets></td><td align="left"><offsets xml_i="29074" xml_f="29083" txt_i="14421" txt_f="14430">132 (12%)</offsets></td><td align="left"><offsets xml_i="29105" xml_f="29114" txt_i="14431" txt_f="14440">552 (35%)</offsets></td><td align="left"><offsets xml_i="29136" xml_f="29145" txt_i="14441" txt_f="14450">565 (47%)</offsets></td><td align="left"><offsets xml_i="29167" xml_f="29176" txt_i="14451" txt_f="14460">693 (41%)</offsets></td><td align="left"><offsets xml_i="29198" xml_f="29207" txt_i="14461" txt_f="14470">426 (35%)</offsets></td><td align="left"><offsets xml_i="29229" xml_f="29238" txt_i="14471" txt_f="14480">714 (42%)</offsets></td><td align="left"><offsets xml_i="29260" xml_f="29269" txt_i="14481" txt_f="14490">618 (48%)</offsets></td><td align="left"><offsets xml_i="29291" xml_f="29300" txt_i="14491" txt_f="14500">823 (45%)</offsets></td></tr><tr><td align="left"><offsets xml_i="29331" xml_f="29351" txt_i="14501" txt_f="14521"> Hydrochlorothiazide</offsets></td><td align="left"><offsets xml_i="29373" xml_f="29380" txt_i="14522" txt_f="14529">22 (2%)</offsets></td><td align="left"><offsets xml_i="29402" xml_f="29411" txt_i="14530" txt_f="14539">157 (10%)</offsets></td><td align="left"><offsets xml_i="29433" xml_f="29442" txt_i="14540" txt_f="14549">272 (22%)</offsets></td><td align="left"><offsets xml_i="29464" xml_f="29473" txt_i="14550" txt_f="14559">326 (19%)</offsets></td><td align="left"><offsets xml_i="29495" xml_f="29504" txt_i="14560" txt_f="14569">168 (14%)</offsets></td><td align="left"><offsets xml_i="29526" xml_f="29535" txt_i="14570" txt_f="14579">335 (20%)</offsets></td><td align="left"><offsets xml_i="29557" xml_f="29566" txt_i="14580" txt_f="14589">334 (26%)</offsets></td><td align="left"><offsets xml_i="29588" xml_f="29597" txt_i="14590" txt_f="14599">424 (23%)</offsets></td></tr><tr><td align="left"><offsets xml_i="29628" xml_f="29643" txt_i="14600" txt_f="14615"> Other AH drugs</offsets></td><td align="left"><offsets xml_i="29665" xml_f="29674" txt_i="14616" txt_f="14625">126 (12%)</offsets></td><td align="left"><offsets xml_i="29696" xml_f="29705" txt_i="14626" txt_f="14635">225 (14%)</offsets></td><td align="left"><offsets xml_i="29727" xml_f="29736" txt_i="14636" txt_f="14645">228 (19%)</offsets></td><td align="left"><offsets xml_i="29758" xml_f="29767" txt_i="14646" txt_f="14655">322 (19%)</offsets></td><td align="left"><offsets xml_i="29789" xml_f="29796" txt_i="14656" txt_f="14663">69 (6%)</offsets></td><td align="left"><offsets xml_i="29818" xml_f="29827" txt_i="14664" txt_f="14673">169 (10%)</offsets></td><td align="left"><offsets xml_i="29849" xml_f="29858" txt_i="14674" txt_f="14683">193 (15%)</offsets></td><td align="left"><offsets xml_i="29880" xml_f="29889" txt_i="14684" txt_f="14693">287 (16%)</offsets></td></tr><tr><td align="left"><offsets xml_i="29920" xml_f="29931" txt_i="14694" txt_f="14705">No AH drugs</offsets></td><td align="left"><offsets xml_i="29953" xml_f="29962" txt_i="14706" txt_f="14715">120 (11%)</offsets></td><td align="left"><offsets xml_i="29984" xml_f="29991" txt_i="14716" txt_f="14723">57 (4%)</offsets></td><td align="left"><offsets xml_i="30013" xml_f="30020" txt_i="14724" txt_f="14731">33 (3%)</offsets></td><td align="left"><offsets xml_i="30042" xml_f="30049" txt_i="14732" txt_f="14739">79 (5%)</offsets></td><td align="left"><offsets xml_i="30071" xml_f="30078" txt_i="14740" txt_f="14747">20 (2%)</offsets></td><td align="left"><offsets xml_i="30100" xml_f="30107" txt_i="14748" txt_f="14755">28 (2%)</offsets></td><td align="left"><offsets xml_i="30129" xml_f="30136" txt_i="14756" txt_f="14763">24 (2%)</offsets></td><td align="left"><offsets xml_i="30158" xml_f="30165" txt_i="14764" txt_f="14771">58 (3%)</offsets></td></tr><tr><td align="left"><offsets xml_i="30196" xml_f="30213" txt_i="14772" txt_f="14789">Treatment unknown</offsets></td><td align="left"><offsets xml_i="30235" xml_f="30237" txt_i="14790" txt_f="14792">NA</offsets></td><td align="left"><offsets xml_i="30259" xml_f="30261" txt_i="14793" txt_f="14795">NA</offsets></td><td align="left"><offsets xml_i="30283" xml_f="30285" txt_i="14796" txt_f="14798">NA</offsets></td><td align="left"><offsets xml_i="30307" xml_f="30313" txt_i="14799" txt_f="14805">7 (0%)</offsets></td><td align="left"><offsets xml_i="30335" xml_f="30337" txt_i="14806" txt_f="14808">NA</offsets></td><td align="left"><offsets xml_i="30359" xml_f="30361" txt_i="14809" txt_f="14811">NA</offsets></td><td align="left"><offsets xml_i="30383" xml_f="30385" txt_i="14812" txt_f="14814">NA</offsets></td><td align="left"><offsets xml_i="30407" xml_f="30413" txt_i="14815" txt_f="14821">5 (0%)</offsets></td></tr></tbody></table><table-wrap-foot><p><sup><offsets xml_i="30464" xml_f="30465" txt_i="14822" txt_f="14823">†</offsets></sup><offsets xml_i="30471" xml_f="30585" txt_i="14823" txt_f="14937">Because many patients were on combined treatment, numbers do not add up. AH, antihypertensive; NA, not applicable.</offsets></p></table-wrap-foot></table-wrap><p><offsets xml_i="30623" xml_f="30965" txt_i="14938" txt_f="15280">At the last follow-up visit, the proportion of patients taking nitrendipine was 68.6% in the diabetic patient group, 72.4 % in the nondiabetic group, 78.3% in the patients who smoke, 71.7% in the nonsmokers group, 77.5% in the patients consuming at least 1 unit of alcohol per day, and 71.4% in the group of nondrinkers or very mild drinkers.</offsets></p></sec><sec><title><offsets xml_i="30987" xml_f="31001" txt_i="15282" txt_f="15296">Blood pressure</offsets></title><p><offsets xml_i="31012" xml_f="31292" txt_i="15297" txt_f="15577">At entry in Syst-Eur2, the mean sitting systolic BP in the patients formerly randomised to placebo was 160.4 ± 16.2 mmHg and in those of the former active-treatment group it was 151.0 ± 14.6 mmHg; the corresponding diastolic levels were 83.4 ± 7.7 mmHg and 79.6 ± 7.8 mmHg (Table </offsets><xref ref-type="table" rid="T1"><offsets xml_i="31324" xml_f="31325" txt_i="15577" txt_f="15578">1</offsets></xref><offsets xml_i="31332" xml_f="31624" txt_i="15578" txt_f="15870">). Of the 3516 patients, 1683 in the former placebo group and 1819 in the former active treatment group had their BP measured at least once during Syst-Eur2. At the last available visit in Syst-Eur2, in the patients of the former control group, the sitting blood pressure had fallen by 15.7 ±</offsets><xref ref-type="fig" rid="F2"><offsets xml_i="31654" xml_f="31655" txt_i="15870" txt_f="15871">2</offsets></xref><offsets xml_i="31662" xml_f="31664" txt_i="15871" txt_f="15873">).</offsets></p><fig position="float" id="F2"><label><offsets xml_i="31705" xml_f="31713" txt_i="15874" txt_f="15882">Figure 2</offsets></label><caption><p><offsets xml_i="31733" xml_f="32062" txt_i="15882" txt_f="16211">Average sitting systolic and diastolic blood pressures at baseline and during follow-up in Syst-Eur 2. Open and closed symbols indicate the patients formerly randomised to placebo or active treatment, respectively. The total number of patients at each follow-up visit is presented separately for the 2 previous arms of the trial.</offsets></p></caption><graphic xlink:href="cvm-2-6-298-2"></graphic></fig><p><offsets xml_i="32131" xml_f="32475" txt_i="16212" txt_f="16556">The between-group differences in systolic and diastolic BP (placebo minus active treatment group) at entry in Syst-Eur 2 were 9.4 mmHg (95% confidence interval [CI] 8.4–10.4 mmHg) and 3.8 mmHg (95% CI 3.3–4.3 mmHg), respectively. At the last visit, these differences were 1.3 mmHg (95% CI 0.4–2.2 mmHg) and 1.2 mmHg (95% CI 0.3–2.1 mmHg) (Fig. </offsets><xref ref-type="fig" rid="F2"><offsets xml_i="32505" xml_f="32506" txt_i="16556" txt_f="16557">2</offsets></xref><offsets xml_i="32513" xml_f="32515" txt_i="16557" txt_f="16559">).</offsets></p><p><offsets xml_i="32522" xml_f="32689" txt_i="16560" txt_f="16727">At baseline in Syst-Eur2, 25.7 % of the patients randomised to placebo and 50.5% of those in the active-treatment group, had a sitting systolic BP less than 150 mmHg (</offsets><italic><offsets xml_i="32697" xml_f="32698" txt_i="16727" txt_f="16728">P</offsets></italic><offsets xml_i="32707" xml_f="32806" txt_i="16728" txt_f="16824"> &lt; 0.001). At the last visit in Syst-Eur2 these proportions were 71.9% and 76.0%, respectively (</offsets><italic><offsets xml_i="32814" xml_f="32815" txt_i="16824" txt_f="16825">P</offsets></italic><offsets xml_i="32824" xml_f="32840" txt_i="16825" txt_f="16841"> = 0.006) (Fig. </offsets><xref ref-type="fig" rid="F3"><offsets xml_i="32870" xml_f="32871" txt_i="16841" txt_f="16842">3</offsets></xref><offsets xml_i="32878" xml_f="32951" txt_i="16842" txt_f="16915">). The percentage of patients reaching the target BP was somewhat lower (</offsets><italic><offsets xml_i="32959" xml_f="32960" txt_i="16915" txt_f="16916">P</offsets></italic><offsets xml_i="32969" xml_f="33293" txt_i="16916" txt_f="17240"> = 0.02) in the diabetic (69.3%) as compared to the nondiabetic patients (74.7%). By contrast, BP control was similar in patients consuming at least 1 unit of alcohol per day (74.6%) as compared to the other patients (74.0%). The proportion of patients reaching goal BP was similar in smokers (75.8%) and nonsmokers (73.9%).</offsets></p><fig position="float" id="F3"><label><offsets xml_i="33334" xml_f="33342" txt_i="17241" txt_f="17249">Figure 3</offsets></label><caption><p><offsets xml_i="33362" xml_f="33723" txt_i="17249" txt_f="17610">Proportion of patients reaching a systolic blood pressure below the target of 150 mmHg at baseline and during follow-up in Syst-Eur 2. Open and closed symbols indicate the patients formerly randomised to placebo or active treatment, respectively. The total number of patients at each follow-up visit is presented separately for the 2 previous arms of the trial.</offsets></p></caption><graphic xlink:href="cvm-2-6-298-3"></graphic></fig><p><offsets xml_i="33792" xml_f="34200" txt_i="17611" txt_f="18019">In the former placebo group, 3.3% of the patients reaching the target BP were not taking any antihypertensive drugs, 36.9% were on nitrendipine only, 44.8% were taking enalapril and/or hydrochlorothiazide, and in 15.0% the study medication was associated with or replaced by other antihypertensive drugs. In the former active treatment group these percentages were 2.2%, 40.4%, 44.1% and 13.3%, respectively.</offsets></p><p><offsets xml_i="34207" xml_f="34433" txt_i="18020" txt_f="18240">The distribution of the last available systolic BP was as follows: 2% &lt;120 mmHg; 9% between 120 and 129 mmHg; 27% between 130 and 139 mmHg; 36% between 140 and 149 mmHg; 14% between 150 and 159 mmHg; 12% &gt;160 mmHg (Fig. </offsets><xref ref-type="fig" rid="F4"><offsets xml_i="34463" xml_f="34464" txt_i="18240" txt_f="18241">4</offsets></xref><offsets xml_i="34471" xml_f="34618" txt_i="18241" txt_f="18382">). Fourteen percent of the patients achieved a diastolic BP &lt;70 mmHg, 47% between 70 and 79 mmHg, 33% between 80 and 89 mmHg and 6% &gt;90 mmHg.</offsets></p><fig position="float" id="F4"><label><offsets xml_i="34659" xml_f="34667" txt_i="18383" txt_f="18391">Figure 4</offsets></label><caption><p><offsets xml_i="34687" xml_f="34920" txt_i="18391" txt_f="18624">Cumulative distributions of systolic blood pressure at the end of Syst-Eur 1 in the placebo and active treatment group and at the last available visit in Syst-Eur 2. The vertical line indicates the goal systolic pressure of 150 mmHg.</offsets></p></caption><graphic xlink:href="cvm-2-6-298-4"></graphic></fig></sec></sec><sec><title><offsets xml_i="35010" xml_f="35020" txt_i="18627" txt_f="18637">Discussion</offsets></title><p><offsets xml_i="35031" xml_f="35197" txt_i="18638" txt_f="18804">This paper describes BP control and compliance with study medications in 3516 older patients with isolated systolic hypertension who are being followed in Syst-Eur2 [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="35228" xml_f="35229" txt_i="18804" txt_f="18805">5</offsets></xref><offsets xml_i="35236" xml_f="36506" txt_i="18805" txt_f="20075">]. We found that substantial reductions in systolic BP could be achieved with a treatment strategy starting with the dihydropyridine calcium-channel blocker, nitrendipine, with the possible addition of enalapril and/or hydrochlorothiazide. At the last available follow-up visit, 74% of the patients had reached a systolic BP level below the target of 150 mmHg and an additional 14% achieved a systolic pressure below 160 mmHg. During Syst-Eur1, systolic BP decreased on average by 22 mmHg in the active-treatment group and by 13 mmHg in the placebo group. During Syst-Eur2, systolic BP further decreased by 7 mmHg and 15 mmHg, respectively. Part of the additional decrease in BP in the former active-treatment group might be due to the early termination of the Syst-Eur trial. Indeed, 261 (7.4%) of the patients participating in Syst-Eur2 had been randomised less than 6 months before the end of Syst-Eur1. In these patients, titration of study medication was probably not yet completed when the trial stopped in February 1997. Indeed, 85% of the active-treatment patients who were randomised less then 6 months before the end of Syst-Eur1 were still on monotherapy with nitrendipine. Another more likely explanation is that the evidence produced by the Syst-Eur trial [</offsets><xref ref-type="bibr" rid="B1"><offsets xml_i="36537" xml_f="36538" txt_i="20075" txt_f="20076">1</offsets></xref><offsets xml_i="36545" xml_f="36546" txt_i="20076" txt_f="20077">,</offsets><xref ref-type="bibr" rid="B2"><offsets xml_i="36577" xml_f="36578" txt_i="20077" txt_f="20078">2</offsets></xref><offsets xml_i="36585" xml_f="36722" txt_i="20078" txt_f="20215">] motivated the investigators to further up-titrate treatment to achieve optimal BP control and greater risk reduction in their patients.</offsets></p><p><offsets xml_i="36729" xml_f="37430" txt_i="20216" txt_f="20917">From the start of the Syst-Eur trial, the Data Monitoring Committee carefully monitored BP control. At yearly intervals all centres received a list of patients who had not yet attained the target BP, together with information on the amount of study medications that these patients were taking. In addition, centres monitoring at least 10 patients received a graph showing the change of BP over time broken down by treatment group. BP control was personally discussed with the investigators at all of the 106 site visits and at the nine meetings for investigators that were held between 1989 and 2000. This quality control program probably contributed to the high rate of BP control currently achieved.</offsets></p><p><offsets xml_i="37437" xml_f="37542" txt_i="20918" txt_f="21023">Syst-Eur2 is an open study that allows the use of antihypertensive treatment other than the study drugs [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="37573" xml_f="37574" txt_i="21023" txt_f="21024">5</offsets></xref><offsets xml_i="37581" xml_f="38187" txt_i="21024" txt_f="21630">]. Nonetheless, a high level of adherence to the study drugs was observed throughout the three initial years of follow-up. At the last available follow-up visit, 72% of the patients were taking nitrendipine and an additional 15% were taking study drugs other than nitrendipine. The withdrawal rate in Syst-Eur2 was also very low. Of the 3358 patients who were still alive on June15, 2000, 90% were still being followed in supervised, open follow-up and another 8.2% in non-supervised, open follow-up. Only 1.8% of the patients without any report within the last 18 months were counted as lost to follow-up.</offsets></p><p><offsets xml_i="38194" xml_f="38243" txt_i="21631" txt_f="21680">Guidelines from the US Joint National Committee [</offsets><xref ref-type="bibr" rid="B7"><offsets xml_i="38274" xml_f="38275" txt_i="21680" txt_f="21681">7</offsets></xref><offsets xml_i="38282" xml_f="38316" txt_i="21681" txt_f="21715">], the World Health Organization [</offsets><xref ref-type="bibr" rid="B8"><offsets xml_i="38347" xml_f="38348" txt_i="21715" txt_f="21716">8</offsets></xref><offsets xml_i="38355" xml_f="38392" txt_i="21716" txt_f="21753">], the British Hypertension Society [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="38423" xml_f="38424" txt_i="21753" txt_f="21754">9</offsets></xref><offsets xml_i="38431" xml_f="38471" txt_i="21754" txt_f="21794">] and the Canadian Medical Association [</offsets><xref ref-type="bibr" rid="B10"><offsets xml_i="38503" xml_f="38505" txt_i="21794" txt_f="21796">10</offsets></xref><offsets xml_i="38512" xml_f="38993" txt_i="21796" txt_f="22277">] all recommend an optimal target systolic BP of 140 mmHg in older hypertensive patients. These guidelines were published only after the protocol of Syst-Eur1 was written (1989). Syst-Eur2 was an extension of the Syst-Eur1 trial and it was decided that the protocols of these two studies should be as similar as possible. The World Health Organization and the British Hypertension Society based their advice mainly on the results of the Hypertension Optimal Treatment (HOT) trial [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="39025" xml_f="39027" txt_i="22277" txt_f="22279">11</offsets></xref><offsets xml_i="39034" xml_f="39460" txt_i="22279" txt_f="22705">]. Comparisons between the three randomised BP target groups (diastolic BP ≤ 90, ≤ 85 or ≤ 80 mmHg), however, showed no differences in cardiovascular outcomes in nondia-betic patients. Based on a Poisson model relating achieved BP to outcome, the optimal BP for reduction of major cardiovascular events was reported to be 139/83 mmHg. Nevertheless, patients whose BPs were below 150/90 mmHg were not apparently disadvantaged [</offsets><xref ref-type="bibr" rid="B9"><offsets xml_i="39491" xml_f="39492" txt_i="22705" txt_f="22706">9</offsets></xref><offsets xml_i="39499" xml_f="39852" txt_i="22706" txt_f="23059">]. In the present population, the threshold of 140 mmHg proposed by the expert committees was reached by 38% of the patients. Because the target BP in the Syst-Eur trial was 150 mmHg, no efforts were undertaken to further lower the BP below 140 mmHg. Moreover, several experts had advised that the diastolic BP should not be lowered much below 70 mmHg [</offsets><xref ref-type="bibr" rid="B12"><offsets xml_i="39884" xml_f="39886" txt_i="23059" txt_f="23061">12</offsets></xref><offsets xml_i="39893" xml_f="39894" txt_i="23061" txt_f="23062">,</offsets><xref ref-type="bibr" rid="B13"><offsets xml_i="39926" xml_f="39928" txt_i="23062" txt_f="23064">13</offsets></xref><offsets xml_i="39935" xml_f="39936" txt_i="23064" txt_f="23065">,</offsets><xref ref-type="bibr" rid="B14"><offsets xml_i="39968" xml_f="39970" txt_i="23065" txt_f="23067">14</offsets></xref><offsets xml_i="39977" xml_f="40062" txt_i="23067" txt_f="23152">]. In the present study, 14% of the patients had a diastolic BP below this threshold.</offsets></p><p><offsets xml_i="40069" xml_f="40286" txt_i="23153" txt_f="23370">Comparison of BP control between various trials is difficult because of the large differences in the BP entry criteria, treatment targets, antihypertensive drugs used and definitions of achieved BP. In the HOT trial [</offsets><xref ref-type="bibr" rid="B11"><offsets xml_i="40318" xml_f="40320" txt_i="23370" txt_f="23372">11</offsets></xref><offsets xml_i="40327" xml_f="41028" txt_i="23372" txt_f="24070">], systolic BP decreased on average by 26 mmHg, 28 mmHg and 30 mmHg in the diastolic BP target groups of ≤ 90 mmHg, ≤ 85 mmHg, and &lt;80 mmHg, respectively. In our study the overall reduction in systolic BP of 29 mmHg was comparable to the changes obtained in the middle and low BP target groups of the HOT trial. Because systolic BP at randomisation was, on average, 3.5 mmHg lower in the HOT trial as compared with the Syst-Eur trial, however, the on-treatment systolic pressure in the Syst-Eur trial (144 mmHg) was similar to the systolic pressure achieved in the highest BP target group of the HOT trial (144 mmHg). In the Swedish Trial in Old Patients with Hypertension-2 (STOP-Hypertension-2) [</offsets><xref ref-type="bibr" rid="B15"><offsets xml_i="41060" xml_f="41062" txt_i="24070" txt_f="24072">15</offsets></xref><offsets xml_i="41069" xml_f="41632" txt_i="24072" txt_f="24629">], patients aged 70–84 years, with moderate to severe hypertension (systolic BP &gt;180 mmHg or diastolic BP &gt;105 mmHg) were randomly assigned conventional antihypertensive drugs (diuretics or β-blockers) or newer drugs (calcium-channel blockers or angiotensin-converting enzyme inhibitors). Target BP was 160/95 mmHg. Systolic BP decreased from 194 mmHg to 158 mmHg in the conventional drug group, 159 mmHg in the angiotensin-converting enzyme inhibitor group and 159 mmHg in the group taking calcium channel blockers. In the Nordic Diltiazem (NORDIL) study [</offsets><xref ref-type="bibr" rid="B16"><offsets xml_i="41664" xml_f="41666" txt_i="24629" txt_f="24631">16</offsets></xref><offsets xml_i="41673" xml_f="42052" txt_i="24631" txt_f="25010">] patients aged 50–74 years with a diastolic BP of at least 100 mmHg were randomised. The treatment target was a diastolic BP below 90 mmHg. Systolic BP was reduced from 173 mmHg to 155 mmHg in the diltiazem group and to 152 mmHg in the groups on older drugs. The percentages of patients reaching the target BP in the HOT, STOP-Hypertension-2 and NORDIL trials were not reported.</offsets></p><p><offsets xml_i="42059" xml_f="42123" txt_i="25011" txt_f="25075">The double-blind International Nifedipine GITS study (INSIGHT) [</offsets><xref ref-type="bibr" rid="B17"><offsets xml_i="42155" xml_f="42157" txt_i="25075" txt_f="25077">17</offsets></xref><offsets xml_i="42164" xml_f="42818" txt_i="25077" txt_f="25731">] recruited patients between 55 and 80 years old with hypertension (BP ≥ 150/95 mmHg, or systolic BP ≥ 160 mmHg) and with at least one additional cardiovascular risk factor. Patients were randomised to nifedipine GITS or co-amilozide. In both treatment groups, systolic BP fell from 173 mmHg to 138 mmHg. Between 54% and 59% of the patients reached the target BP, which was defined as a decrease in BP by at least 20/10 mmHg to a level below 140/90 mmHg. In the INSIGHT study, however, an intention-to-treat analysis of BP responses was not presented. Finally, in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) [</offsets><xref ref-type="bibr" rid="B18"><offsets xml_i="42850" xml_f="42852" txt_i="25731" txt_f="25733">18</offsets></xref><offsets xml_i="42859" xml_f="43345" txt_i="25733" txt_f="26213">], hypertensive patients (systolic BP ≥ 140 mmHg or diastolic BP ≥ 90 mmHg) aged ≥ 55 years with at least one additional risk factor, were randomised to double-blind treatment with four types of antihypertensive drugs. Systolic BP fell from 145 mmHg at baseline to 136 mmHg at two years in the chlorthalidone group and to 138 mmHg in the doxazosin group. The percentages of patients reaching the target BP (&lt;140 mmHg systolic and &lt;90 mmHg diastolic) were 61% and 54% respectively.</offsets></p></sec><sec><title><offsets xml_i="43367" xml_f="43377" txt_i="26215" txt_f="26225">Conclusion</offsets></title><p><offsets xml_i="43388" xml_f="43792" txt_i="26226" txt_f="26630">On June 15, 2000, 90% of the patients entering Syst-Eur2 in 1997 were still being followed in supervised, open follow-up and 72% of the patients were still on nitrendipine as first-line treatment. 74% of the patients achieved a systolic BP below the target of 150 mmHg. The main results of the Syst-Eur2 study will be reported in the year 2002. Additional information can be found on the trial web site [</offsets><xref ref-type="bibr" rid="B20"><offsets xml_i="43824" xml_f="43826" txt_i="26630" txt_f="26632">20</offsets></xref><offsets xml_i="43833" xml_f="43835" txt_i="26632" txt_f="26634">].</offsets></p></sec><sec><title><offsets xml_i="43857" xml_f="43876" txt_i="26636" txt_f="26655">Competing interests</offsets></title><p><offsets xml_i="43887" xml_f="43901" txt_i="26656" txt_f="26670">None declared.</offsets></p></sec><sec><title><offsets xml_i="43923" xml_f="43936" txt_i="26672" txt_f="26685">Abbreviations</offsets></title><p><offsets xml_i="43947" xml_f="44380" txt_i="26686" txt_f="27119">ALLHAT = Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; HOT = Hypertension Optimal Treatment trial; INSIGHT = International Nifedipine GITS study; NORDIL = Nordic Diltiazem study; STOP-Hypertension-2 = Swedish Trial in Old Patients with Hypertension-2; Syst-Eur = Systolic Hypertension in Europe trial; Syst-Eur 2 = Systolic Hypertension in Europe Phase 2. BP = blood pressure; CI = confidence interval.</offsets></p></sec><sec><title><offsets xml_i="44402" xml_f="44410" txt_i="27121" txt_f="27129">Appendix</offsets></title><sec><title><offsets xml_i="44430" xml_f="44448" txt_i="27130" txt_f="27148">Trial coordinators</offsets></title><p><offsets xml_i="44459" xml_f="44500" txt_i="27149" txt_f="27190">Robert Fagard, MD and Jan A Staessen, MD.</offsets></p></sec><sec><title><offsets xml_i="44522" xml_f="44543" txt_i="27192" txt_f="27213">Regional coordinators</offsets></title><p><offsets xml_i="44554" xml_f="45070" txt_i="27214" txt_f="27730">Guramy G Arabidze, MD (deceased) (Bellorussia and the Russian Federation); Willem H Birkenhäger, MD (the Netherlands); Christopher J Bulpitt, MD (United Kingdom); Manuel Carrageta, MD (Portugal); Hilde Celis, MD (Belgium); Françoise Forette, MD (France); Jozef Kocemba, MD (Poland); Gastone Leonetti, MD (Italy); Choudomir Nachev, MD (Bulgaria); Eoin T O'Brien, MD (Ireland); Eberhard Ritz, MD (Germany); José L Rodicio, MD (Spain); Joseph Rosen-feld, MD (Israel); Jaakko Tuomilehto (Finland, Estonia and Lithuania).</offsets></p></sec><sec><title><offsets xml_i="45092" xml_f="45110" txt_i="27732" txt_f="27750">Steering committee</offsets></title><p><offsets xml_i="45121" xml_f="45407" txt_i="27751" txt_f="28037">Guramy G Arabidze, MD (deceased); Paul De Cort, MD; Robert Fagard, MD; Françoise Forette, MD; Kalina Kawecka-Jaszcz, MD; Gastone Leonetti, MD; Choudomir Nachev, MD; Eoin T O'Brien, MD; José L Rodico, MD; Joseph Rosenfeld, MD; Jaakko Tuomilehto, MD; John Webster, MD and Yair Yodfat, MD.</offsets></p></sec><sec><title><offsets xml_i="45429" xml_f="45454" txt_i="28039" txt_f="28064">Data monitoring committee</offsets></title><p><offsets xml_i="45465" xml_f="45559" txt_i="28065" txt_f="28159">Christopher J Bulpitt, MD; Astrid E Fletcher, PhD; Jan A Staessen, MD and Lutgarde Thijs, BSc.</offsets></p></sec><sec><title><offsets xml_i="45581" xml_f="45600" txt_i="28161" txt_f="28180">End-point committee</offsets></title><p><offsets xml_i="45611" xml_f="45697" txt_i="28181" txt_f="28267">Peter W de Leeuw, MD; Robert Fagard, MD; Gastone Leonetti, MD and James C. Petrie, MD.</offsets></p></sec><sec><title><offsets xml_i="45719" xml_f="45735" txt_i="28269" txt_f="28285">Ethics Committee</offsets></title><p><offsets xml_i="45746" xml_f="45814" txt_i="28286" txt_f="28354">Willem H Birkenhäger, MD; Colin T Dollery, MD and Robert Fagard, MD;</offsets></p></sec><sec><title><offsets xml_i="45836" xml_f="45857" txt_i="28356" txt_f="28377">Publication Committee</offsets></title><p><offsets xml_i="45868" xml_f="45966" txt_i="28378" txt_f="28476">Willem H Birkenhäger, MD; Christopher J Bulpitt, MD; Jan A Staessen, MD and Alberto Zanchetti, MD.</offsets></p></sec><sec><title><offsets xml_i="45988" xml_f="46007" txt_i="28478" txt_f="28497">Coordinating office</offsets></title><p><offsets xml_i="46018" xml_f="46276" txt_i="28498" txt_f="28756">Nicole Ausseloos; Hilde Celis, MD; Elly Den Hond, DSc; Lut De Pauw, RN; Paul Drent; Robert Fagard, MD; Heng Fan; Tim Nawrot, BSc; Yvette Piccart; Jan A Staessen, MD; Yvette Toremans; Lutgarde Thijs, BSc; Sylvia Van Hulle, RN; Ji G Wang, MD and Renilde Wolfs.</offsets></p></sec><sec><title><offsets xml_i="46298" xml_f="46314" txt_i="28758" txt_f="28774">Clinical centres</offsets></title><p><offsets xml_i="46325" xml_f="46375" txt_i="28775" txt_f="28825">The clinical investigators are listed in Staessen </offsets><italic><offsets xml_i="46383" xml_f="46389" txt_i="28825" txt_f="28831">et al.</offsets></italic><offsets xml_i="46398" xml_f="46400" txt_i="28831" txt_f="28833"> [</offsets><xref ref-type="bibr" rid="B19"><offsets xml_i="46432" xml_f="46434" txt_i="28833" txt_f="28835">19</offsets></xref><offsets xml_i="46441" xml_f="46456" txt_i="28835" txt_f="28850">] and Gasowski </offsets><italic><offsets xml_i="46464" xml_f="46469" txt_i="28850" txt_f="28855">et al</offsets></italic><offsets xml_i="46478" xml_f="46481" txt_i="28855" txt_f="28858">. [</offsets><xref ref-type="bibr" rid="B5"><offsets xml_i="46512" xml_f="46513" txt_i="28858" txt_f="28859">5</offsets></xref><offsets xml_i="46520" xml_f="46522" txt_i="28859" txt_f="28861">].</offsets></p></sec></sec></body><back><ack><sec><title>Acknowledgements</title><p>The Syst-Eur trial, initiated by the late Prof A Amery, was a concerted action of the BIOMED Research Program sponsored by the European Union. The trial was carried out in consultation with the World Health Organisation, the International Society of Hypertension, the European Society of Hypertension and the World Hypertension League. Syst-Eur 2 is sponsored by Bayer AG (Wuppertal, Germany). The study medication is donated by Bayer AG and Merck Sharpe and Dohme Inc (West Point, PA, USA).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Thijs</surname><given-names>L</given-names></name><name><surname>Celis</surname><given-names>H</given-names></name><name><surname>Arabidze</surname><given-names>G</given-names></name><name><surname>Birkenhäger</surname><given-names>WH</given-names></name><name><surname>Bulpitt</surname><given-names>CJ</given-names></name><name><surname>de Leeuw</surname><given-names>PW</given-names></name><name><surname>Dollery</surname><given-names>CT</given-names></name><name><surname>Fletcher</surname><given-names>AE</given-names></name><name><surname>Forette</surname><given-names>F</given-names></name><name><surname>Leonetti</surname><given-names>G</given-names></name><name><surname>Nachev</surname><given-names>C</given-names></name><name><surname>O'Brien</surname><given-names>ET</given-names></name><name><surname>Rosenfeld</surname><given-names>J</given-names></name><name><surname>Rodicio</surname><given-names>JL</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><collab>for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators</collab></person-group><article-title>Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.</article-title><source>Lancet</source><year>1997</year><volume>350</volume><fpage>757</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">9297994</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(97)05381-6</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Thijs</surname><given-names>L</given-names></name><name><surname>Birkenhäger</surname><given-names>WH</given-names></name><name><surname>Bulpitt</surname><given-names>CJ</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><collab>on behalf of the Syst-Eur investigators</collab></person-group><article-title>Update on the Systolic Hypertension in Europe (Syst-Eur) Trial.</article-title><source>Hypertension</source><year>1999</year><volume>33</volume><fpage>1476</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">10373236</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>JG</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>G</given-names></name><name><surname>Staessen</surname><given-names>JA</given-names></name><collab>for the Systolic Hypertension in China (Syst-China) Collaborative Group</collab></person-group><article-title>Comparison of active treatment and placebo for older patients with isolated systolic hypertension.</article-title><source>J Hypertens</source><year>1998</year><volume>16</volume><fpage>1823</fpage><lpage>1829</lpage><pub-id pub-id-type="pmid">9869017</pub-id><pub-id pub-id-type="doi">10.1097/00004872-199816120-00016</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>J</given-names></name><collab>11 collaborating centres in the Shangai area</collab><name><surname>Kong</surname><given-names>D</given-names></name><name><surname>Page</surname><given-names>V</given-names></name><name><surname>Ghadirian</surname><given-names>P</given-names></name><name><surname>LaLorier</surname><given-names>J</given-names></name><name><surname>Hamet</surname><given-names>P</given-names></name></person-group><article-title>Shanghai trial of nifedipine in the elderly (STONE).</article-title><source>J Hypertens</source><year>1996</year><volume>14</volume><fpage>1237</fpage><lpage>1245</lpage><pub-id pub-id-type="pmid">8906524</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gasowski</surname><given-names>J</given-names></name><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Celis</surname><given-names>H</given-names></name><name><surname>Fagard</surname><given-names>RH</given-names></name><name><surname>Thijs</surname><given-names>L</given-names></name><name><surname>Birkenhäger</surname><given-names>WH</given-names></name><name><surname>Bulpitt</surname><given-names>CJ</given-names></name><name><surname>Fletcher</surname><given-names>AE</given-names></name><name><surname>Arabidze</surname><given-names>GG</given-names></name><name><surname>de Leeuw</surname><given-names>PW</given-names></name><name><surname>Dollery</surname><given-names>CT</given-names></name><name><surname>Duggan</surname><given-names>J</given-names></name><name><surname>Kawecka-Jaszcz</surname><given-names>K</given-names></name><name><surname>Leonetti</surname><given-names>G</given-names></name><name><surname>Nachev</surname><given-names>C</given-names></name><name><surname>Safar</surname><given-names>M</given-names></name><name><surname>Rodicio</surname><given-names>JL</given-names></name><name><surname>Rosenfeld</surname><given-names>J</given-names></name><name><surname>Seux</surname><given-names>ML</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Webster</surname><given-names>J</given-names></name><name><surname>Yodfat</surname><given-names>Y</given-names></name><collab>on behalf of the Systolic Hypertension in Europe Investigators</collab></person-group><article-title>Systolic Hypertension in Europe (Syst-Eur) Trial Phase 2: objectives, protocol, and initial progress.</article-title><source>J Hum Hypertens</source><year>1999</year><volume>13</volume><fpage>135</fpage><lpage>145</lpage><pub-id pub-id-type="pmid">10100063</pub-id><pub-id pub-id-type="doi">10.1038/sj/jhh/1000769</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><collab>41st World Medical Assembly</collab></person-group><article-title>Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects.</article-title><source>Bull Pan Am Health Organ</source><year>1990</year><volume>24</volume><fpage>606</fpage><lpage>609</lpage></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><collab>The Joint National Committee on Detection Evaluation and Treatmentof Hypertension</collab></person-group><article-title>The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC-VI).</article-title><source>Arch Intern Med</source><year>1997</year><volume>157</volume><fpage>2413</fpage><lpage>2446</lpage><pub-id pub-id-type="pmid">9385294</pub-id><pub-id pub-id-type="doi">10.1001/archinte.157.21.2413</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><collab>International Society of Hypertension Guidelines Subcommittee</collab></person-group><article-title>1999 World Health Organization – International Society of Hypertension Guidelines for the Management of Hypertension.</article-title><source>J Hypertens</source><year>1999</year><volume>17</volume><fpage>151</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">10067786</pub-id><pub-id pub-id-type="doi">10.1097/00004872-199917020-00001</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ramsay</surname><given-names>LE</given-names></name><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Johnston</surname><given-names>GD</given-names></name><name><surname>MacGregor</surname><given-names>GA</given-names></name><name><surname>Poston</surname><given-names>L</given-names></name><name><surname>Potter</surname><given-names>JF</given-names></name><name><surname>Poulter</surname><given-names>NR</given-names></name><name><surname>Russell</surname><given-names>G</given-names></name></person-group><article-title>British Hypertension Society guidelines for hypertension management 1999: summary.</article-title><source>BMJ</source><year>1999</year><volume>319</volume><fpage>630</fpage><lpage>635</lpage><pub-id pub-id-type="pmid">10473485</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feldman</surname><given-names>RD</given-names></name><name><surname>Campbell</surname><given-names>N</given-names></name><name><surname>Larochelle</surname><given-names>P</given-names></name><collab>for the Task Force for the Development of the 1999 Canadian Recommendations for the Management of Hypertension</collab></person-group><article-title>Canadian Recommendations for the Management of Hypertension.</article-title><source>Can Med Assoc J</source><year>1999</year><volume>161 (Suppl 12)</volume><fpage>S1</fpage><lpage>S17</lpage><pub-id pub-id-type="pmid">10624417</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>L</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><name><surname>Carruthers</surname><given-names>SG</given-names></name><name><surname>Dahlöf</surname><given-names>B</given-names></name><name><surname>Elmfeldt</surname><given-names>D</given-names></name><name><surname>Julius</surname><given-names>S</given-names></name><name><surname>Ménard</surname><given-names>J</given-names></name><name><surname>Rahn</surname><given-names>KH</given-names></name><name><surname>Wedel</surname><given-names>H</given-names></name><name><surname>Westerling</surname><given-names>S</given-names></name><collab>for the HOT Study Group</collab></person-group><article-title>Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial.</article-title><source>Lancet</source><year>1998</year><volume>351</volume><fpage>1755</fpage><lpage>1762</lpage><pub-id pub-id-type="pmid">9635947</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(98)04311-6</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>N</given-names></name></person-group><article-title>New issues in the treatment of isolated systolic hypertension.</article-title><source>Circulation</source><year>2000</year><volume>102</volume><fpage>1079</fpage><lpage>1081</lpage><pub-id pub-id-type="pmid">10973833</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Somes</surname><given-names>GW</given-names></name><name><surname>Pahor</surname><given-names>M</given-names></name><name><surname>Shorr</surname><given-names>RI</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Applegate</surname><given-names>WB</given-names></name></person-group><article-title>The role of diastolic blood pressure when treating isolated systolic hypertension.</article-title><source>Arch Intern Med</source><year>1999</year><volume>159</volume><fpage>2004</fpage><lpage>2009</lpage><pub-id pub-id-type="pmid">10510985</pub-id><pub-id pub-id-type="doi">10.1001/archinte.159.17.2004</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voko</surname><given-names>Z</given-names></name><name><surname>Bots</surname><given-names>ML</given-names></name><name><surname>Hofman</surname><given-names>A</given-names></name><name><surname>Koudstaal</surname><given-names>PJ</given-names></name><name><surname>Witteman</surname><given-names>JCM</given-names></name><name><surname>Breteler</surname><given-names>MMB</given-names></name></person-group><article-title>J-shaped relation between blood pressure and stroke in treated hypertensives.</article-title><source>Hypertension</source><year>1999</year><volume>34</volume><fpage>1181</fpage><lpage>1185</lpage><pub-id pub-id-type="pmid">10601115</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>L</given-names></name><name><surname>Lindholm</surname><given-names>L</given-names></name><name><surname>Ekbom</surname><given-names>T</given-names></name><name><surname>Dahlöf</surname><given-names>B</given-names></name><name><surname>Lanke</surname><given-names>J</given-names></name><name><surname>Scherstén</surname><given-names>B</given-names></name><name><surname>Wester</surname><given-names>P-O</given-names></name><name><surname>Hedner</surname><given-names>T</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name><collab>for the STOP-Hypertension-2 study group</collab></person-group><article-title>Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study.</article-title><source>Lancet</source><year>2000</year><volume>354</volume><fpage>1751</fpage><lpage>1756</lpage><pub-id pub-id-type="pmid">10577635</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(99)10327-1</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hansson</surname><given-names>L</given-names></name><name><surname>Hedner</surname><given-names>T</given-names></name><name><surname>Lund-Johansen</surname><given-names>P</given-names></name><name><surname>Kjeldsen</surname><given-names>SE</given-names></name><name><surname>Lindholm</surname><given-names>LH</given-names></name><name><surname>Syvertsen</surname><given-names>JO</given-names></name><name><surname>Lanke</surname><given-names>J</given-names></name><name><surname>de Faire</surname><given-names>U</given-names></name><name><surname>Dahlöf</surname><given-names>B</given-names></name><name><surname>Karlberg</surname><given-names>BE</given-names></name><collab>for the NORDIL Study Group</collab></person-group><article-title>Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study.</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>359</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">10972367</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02526-5</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MJ</given-names></name><name><surname>Palmer</surname><given-names>CR</given-names></name><name><surname>Castaigne</surname><given-names>A</given-names></name><name><surname>de Leeuw</surname><given-names>PW</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Rosenthal</surname><given-names>T</given-names></name><name><surname>Ruilope</surname><given-names>LM</given-names></name></person-group><article-title>Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT).</article-title><source>Lancet</source><year>2000</year><volume>356</volume><fpage>366</fpage><lpage>372</lpage><pub-id pub-id-type="pmid">10972368</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(00)02527-7</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><collab>The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group</collab></person-group><article-title>Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT).</article-title><source>JAMA</source><year>2000</year><volume>283</volume><fpage>1967</fpage><lpage>1975</lpage><pub-id pub-id-type="pmid">10789664</pub-id><pub-id pub-id-type="doi">10.1001/jama.283.15.1967</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Staessen</surname><given-names>JA</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Thijs</surname><given-names>L</given-names></name><name><surname>Celis</surname><given-names>H</given-names></name><name><surname>Birkenhäger</surname><given-names>WH</given-names></name><name><surname>Bulpitt</surname><given-names>CJ</given-names></name><name><surname>de Leeuw</surname><given-names>PW</given-names></name><name><surname>Fletcher</surname><given-names>AE</given-names></name><name><surname>Babarskiene</surname><given-names>M-R</given-names></name><name><surname>Forette</surname><given-names>F</given-names></name><name><surname>Kocembe</surname><given-names>J</given-names></name><name><surname>Laks</surname><given-names>T</given-names></name><name><surname>Leonetti</surname><given-names>G</given-names></name><name><surname>Nachev</surname><given-names>C</given-names></name><name><surname>Petrie</surname><given-names>JC</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>Vanhanen</surname><given-names>H</given-names></name><name><surname>Webster</surname><given-names>J</given-names></name><name><surname>Yodfat</surname><given-names>Y</given-names></name><name><surname>Zanchetti</surname><given-names>A</given-names></name><collab>for the Systolic Hypertension in Europe Trial Investigators</collab></person-group><article-title>Subgroup and perprotocol analysis of the randomised European trial on isolated systolic hypertension in the elderly.</article-title><source>Arch Intern Med</source><year>1998</year><volume>158</volume><fpage>1681</fpage><lpage>1691</lpage><pub-id pub-id-type="pmid">9701103</pub-id><pub-id pub-id-type="doi">10.1001/archinte.158.15.1681</pub-id></citation></ref><ref id="B20"><citation citation-type="other"><article-title>Syst-Eur</article-title><ext-link ext-link-type="uri" xlink:href="http://www.syst-eur.com"></ext-link></citation></ref></ref-list></back></article>